Podcasts about Duchenne

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into groundbreaking scientific advancements, crucial regulatory updates, and strategic industry movements that are shaping the future of patient care and drug development. AstraZeneca, in collaboration with Daiichi Sankyo, has achieved a significant milestone with their antibody-drug conjugate, Enhertu, combined with Roche's Perjeta. This combination therapy has recently secured European Union approval for first-line treatment of HER2-positive metastatic breast cancer. The approval highlights the transformative potential of antibody-drug conjugates in treating aggressive breast cancer subtypes. Enhertu targets HER2-positive tumors by delivering cytotoxic agents directly to the cancer cells, thereby minimizing off-target effects and enhancing efficacy. Such innovations underscore the industry's commitment to improving therapeutic outcomes for patients facing complex medical challenges. In another notable development, Novartis has entered into a substantial $3.2 billion licensing agreement with Alteogen, focusing on ALT-B4 hyaluronidase technology. This collaboration emphasizes the growing interest in subcutaneous drug formulations that offer improved patient compliance and convenience compared to traditional intravenous routes. Hyaluronidase helps disperse and absorb subcutaneously injected drugs more efficiently by degrading hyaluronic acid in tissues, thereby enhancing bioavailability and reducing injection volumes. Shifting gears to clinical trial advancements, Hutchmed's combination therapy featuring Tagrisso (osimertinib) and Orpathys (savolitinib) has achieved a Phase 3 success in first-line treatment for MET-overexpressing non-small cell lung cancer. This marks an important stride towards personalized medicine approaches that target specific genetic mutations driving tumor growth. The success of this combination therapy points to a future where targeted treatments become more prevalent in addressing complex oncogenic drivers. In the realm of strategic partnerships, Novacyt and Illumina have embarked on a five-year collaboration focusing on diagnostics and DNA sequencing technologies. This partnership aims to leverage Illumina's genomic sequencing expertise to advance precision medicine efforts in diagnostics, further highlighting the importance of collaborations in overcoming technological hurdles. Meanwhile, in gene therapy developments, NewBiologix and Synastra Biotechnology have joined forces to develop stable recombinant adeno-associated viral cell lines for Duchenne muscular dystrophy therapies. Their partnership aims to address manufacturing challenges associated with gene therapies for rare diseases, potentially accelerating treatment availability for patients in need. Despite these promising advancements, the industry is not without its challenges. Cellares recently announced significant job cuts following the loss of a contract with Bristol Myers Squibb for cell therapy production. Additionally, regulatory scrutiny remains high as evidenced by the UK Medicines and Healthcare products Regulatory Agency's suspension of Amgen's Tavneos amid concerns over trial data integrity. Such developments underscore the critical importance of maintaining rigorous data standards in drug development. Turning our attention to regulatory dynamics, the Trump administration has introduced a new drug pricing model under Medicare, providing weight loss medications at reduced prices for eligible seniors. This initiative involves major players like Eli Lilly and Novo Nordisk and aims to enhance access to obesity treatments for seniors—a move that could signify a shift towards preventive healthcare. On the clinical front, Alnylam Pharmaceuticals' next-generation gene-silencing technology shows promise for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Despite setbacks faced by AstraZeneca and Ionis Pharmaceuticals in similar trials, Alnylam's approach holds potential when used alongside standard treatments. The pharmaceutical sector also sees evolving market dynamics with reverse mergers rising sharply by 1,600% in Q3. This trend rivals traditional IPOs as companies seek alternative routes to liquidity amid fluctuating investor sentiments. Such strategic adaptations reflect the industry's resilience amidst economic uncertainties. In conclusion, these developments paint a picture of an industry dynamically adapting to technological advancements, regulatory changes, and market demands. From innovative drug delivery technologies to strategic partnerships and robust regulatory frameworks, the sector remains committed to advancing precision medicine and improving patient care globally. As these trends continue to unfold, they promise significant implications for drug development processes and therapeutic paradigms across various disease landscapes.Support the show

Episode 195: Re-release, Episode 106 of the American Grown Podcast in the Colortech Creative Solutions studios with Jon Simpson, Personal Care Assistant.•In this episode, I re-released episode 106 featuring Jon Simpson. Jon shares his journey to becoming a Personal Care Assistant and the meaningful work he does supporting students at Cedar Crest High School.Jon currently works alongside Sully's cousin, Levi Hains, who lives with Duchenne muscular dystrophy. We talk about the importance of support, friendship, and showing up for the people around us.We also dive into the culture at Cedar Crest, Jon's passion for Penn State sports, and what makes being part of a community so special.Jon and Sully wrap up the conversation with a simple but powerful reminder: being present, being kind, and treating people well can make a bigger impact than we realize.Sometimes making the world a better place starts with simply showing up.

A diagnosis can change your life, but it does not have to decide what comes next. My guest Paul Bugeja has built a life shaped by curiosity, career change, travel, creativity, and a determination to keep moving forward. Paul lives with facioscapulohumeral muscular dystrophy, or FSHD, a condition he calls his “dark angel.” We talk about how disability has influenced his choices without defining them, why staying active matters to him, and how personal agency has helped him face uncertainty without becoming trapped by fear. Paul also shares his path from acting and writing into journalism and digital media, where he now works as a quizmaster. We explore disability advocacy, media accessibility, the role of AI in journalism, and the danger of losing critical thinking. Paul's story reminds us that resilience is not about denying challenges. It is about understanding them while continuing to choose how we live. Highlights: 01:10 – How moving often helped Paul learn to adapt. 12:15 – How a gym visit led to his FSHD diagnosis. 20:39 – Why disability gave Paul a stronger drive to live fully. 22:53 – How knowledge of his condition gave him more agency. 38:35 – Why accessible media still has room to improve. 45:57 – How staying present helps Paul manage worry and fear. About the Guest: Working as a quizmaster for a major media organisation isn't somewhere I could have predicted I'd end up professionally, but, then again, life has taken so many twists and turns it doesn't surprise me this is where I currently find myself. Despite early aspirations to be an actor, I completed a double degree in Arts and Commerce at the University of Melbourne, with the final year spent on exchange at UC Berkeley, California. On my return to Australia, not to be denied, the ever-persistent actor in me got me admission to the prestigious Victorian College of the Arts Drama School: the decade or so following saw me immersed in the challenging but exciting life of the struggling actor. This period was also the launching pad into studies in writing, editing, journalism and screenwriting, which I did as I worked in book publishing and wrote half a dozen books, even as I edged into the rapidly evolving professional world of content, digital marketing and journalism. Throughout this entire time, I've lived alongside and managed my “dark angel”—a diagnosis of facioscapulohumeral muscular dystrophy—which has only served to galvanise me further to live a life less ordinary along the road less travelled … And that has made all the difference. Ways to connect with Paul**:** LinkedIn https://www.linkedin.com/in/peebee/ About the Host: Michael Hingson is a New York Times best-selling author, international lecturer, and Chief Vision Officer for accessiBe. Michael, blind since birth, survived the 9/11 attacks with the help of his guide dog Roselle. This story is the subject of his best-selling book, Thunder Dog. Michael gives over 100 presentations around the world each year speaking to influential groups such as Exxon Mobile, AT&T, Federal Express, Scripps College, Rutgers University, Children's Hospital, and the American Red Cross just to name a few. He is Ambassador for the National Braille Literacy Campaign for the National Federation of the Blind and also serves as Ambassador for the American Humane Association's 2012 Hero Dog Awards. https://michaelhingson.com https://www.facebook.com/michael.hingson.author.speaker/ https://twitter.com/mhingson https://www.youtube.com/user/mhingson https://www.linkedin.com/in/michaelhingson/ Thanks for listening! Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below! Subscribe to the podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can subscribe in your favorite podcast app. You can also support our podcast through our tip jar https://tips.pinecast.com/jar/unstoppable-mindset . Leave us an Apple Podcasts review Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts. Transcription Notes: Michael Hingson  00:04 What if the biggest thing holding you back isn't what's in front of you, but rather what you believe? Welcome to Unstoppable Mindset, where inclusion, diversity, and the unexpected meet. I'm your host, Michael Hingston, speaker, author, and advocate for inclusion and possibilities. This podcast explores how the beliefs we carry shape the way we live, lead, and connect with others. Each week, I talk with people who challenge assumptions, face adversity head-on, and show what's possible when we choose curiosity over fear. Together, we focus on mindset, resilience, and the small shifts that lead to meaningful change. Let's get started. Hi, everyone. I'd like to thank you once again for coming to another episode of Unstoppable Mindset. And if you're new to the podcast, we hope you enjoy our episode today. We're glad you're here wherever you may happen to be. Today we are communicating a long way away. We're communicating with Melbourne, Australia, to Paul Bugeja, and Paul is fondly known as a quizmaster. We're going to have to find out more about that, but he's had a lot of interest in acting and media and such things as that, and has had clearly a pretty adventurous life. And again, I'm sure we're going to hear a lot about a lot of that today. So, Paul, welcome to Unstoppable Mindset. We're really glad you're here. Paul Bugeja  01:44 Thank you for having me, Michael. Michael Hingson  01:46 So why don't we start? I love to do this with the early Paul, kind of growing up and how things all got started. If you remember back that far, or at least as far back as you remember, or what you were told anyway. Paul Bugeja  01:59 You know, pretty standard like childhood story for me. Grew up in the green leafy sort of suburbs of Melbourne. You know, did all the things that kids do in their growing up years. My my mother actually divorced my father quite young for me, so that was a little bit of a a critical sort of point for a child to sort of, you know, have to grapple with, but um, it was pretty smooth, and you know, um, it didn't really disrupt my childhood, except it meant that I moved around a lot when I was quite young. So I probably moved about seven or eight times by the time I was maybe eight years old. Um, but I think, in a way, that that that sort of has worked for me because it meant that even as a young child, I had to learn to adapt and change and evolve very quickly. Particularly when it came to meeting people, and you know, as a child, obviously making friends-that's one of the trickiest parts as a kid sometimes. So I think that actually stood me in good stead in in that regard, yeah. Michael Hingson  03:04 Well, I I didn't have to move a whole lot growing up. We moved from Chicago to California when I was five and stayed in the same house since college. I have moved a bunch of times, but those things happen. I understand what you're saying. I'm I'm used to it, but am am of the opinion that I'd rather not move again. It is a lot of work to move, and now also it's just me. My wife passed away two almost two and a half years ago, so I don't want to pack and move again. But yeah, well, we're in a house that we built, and and so we built it really around her because she's in a wheelchair her whole life. So it's an accessible house, but it's a very comfortable house. So I I have no complaints, and and the dog and the cat seem to like it as well. So we're here. Paul Bugeja  04:01 It's a win for everyone, and I think look, that's that's a really interesting. I had this very similar conversation with a friend yesterday about there's a time to put down roots and there's a time to be a you know a rolling stone, and and for some people that's at different times in their life, you know. So I I can understand why you would have chosen to find your comfy spot to settle into and enjoy. Michael Hingson  04:23 Well, and I have a good mortgage rate and all that, so yeah, we're happy with with things the way they are. And as long as the dog and the cat are happy, I can't complain a bit. Paul Bugeja  04:33 Excellent, excellent. Michael Hingson  04:34 But but now you're and and you you're not moving as much around anymore. Paul Bugeja  04:40 Sort of the opposite, actually. I think, like, to to go back to what we were originally discussing. Like, I think having moved so much as a younger person has meant I've lived a life that's almost constantly moving. Like, there certainly have been periods where I've lived for reasonably long periods in the one place, but particularly over the past. We maybe 10 to 12 years or so. I've moved like literally maybe 10 to 12 times. Like it's becoming, Michael Hingson  05:09 it Paul Bugeja  05:10 almost becomes a bit addictive. Sort of the ability to to be transportable when your professional life allows you and your personal life allows you as well. Michael Hingson  05:18 Yeah, I can understand that. For me, I don't want to go through all the rigors of packing and finding a new home and all that, so we're good. But but it it's okay because I can go anywhere from here, and so that works out pretty well. So I'm I'm content, and that that's the way it it should be. So we'll see how it all goes. But I'm glad that you did well, so you grew up, had kind of a normal life, even though you moved around a lot. Yeah, did all the things that that that kids do growing up, and so on. And where did you go to college, or did you? Paul Bugeja  05:53 Yeah, so I my original, I've I was a bit of a perpetual student for probably you know the first several decades as an adult, my original degree was from the University of Melbourne, which is one of the sort of larger universities in both Melbourne and Australia, and I did a double degree in arts and commerce. But you know, I had long wanted to be an actor, and so originally, like when I finished high school, my my intention was to audition for drama school. But my mother very wisely convinced me to go to university first, and then check that out. And if I didn't like it, then maybe audition for drama school a bit later on. And it was, as mothers can be on most occasions, very sagely advice from her, because the thing that she wasn't aware of was that even though I I definitely enjoyed the academic aspect of my studies at MLB Uni, it has a very strong theater department as well, and very big names have actually been through there and gone on to bigger and better things, namely Kate Blanchett. She was one of my colleagues back in the day. So you know, it was a it was a proving ground for talent. And so I did a lot of theater during my my studies at the University of Melbourne while completing the academic side as well. So I never quite lost that sort of underlying desire to maybe go on and and study acting and maybe do some acting. I actually completed the final year of my degree at Cal at UC Berkeley, which was an amazing experience, and sort of also launched me into the next part of my life. So that that was at a time when you know, like I think in a lot of ways, more and more students were traveling between countries to study. It was becoming a real thing to study overseas, so it was such an amazing experience to finish at Cal. Michael Hingson  07:48 So, do you keep in touch with Kate at Paul Bugeja  07:52 all? Haven't seen Kate in probably maybe 20 years or so. We kept in contact during the beginning of her career, of course, and then you know that life has taken her to such places that it's almost impossible to keep Michael Hingson  08:07 touch, right? Paul Bugeja  08:08 That's right. But you know, I dare say, if I think she's probably maintained the sort of personality and character that she had when I knew her, which would mean that if I bumped into her on the street and I said hello and gave her a bit of a nudge about where we knew each other from. She'd be the first one to lean into that and and you know be quite happy to reminisce on old times as you know she's not an aloof sort of person. I think that's my feel about her, even given her amazing success. Michael Hingson  08:37 I've never had that impression of her either, so I I'm with you. Well, that's pretty cool. What What took you to Berkeley for your last year? Paul Bugeja  08:45 Yeah, so I actually started working during my studies on campus at the university, and I worked in the international student office. So I was dealing with a lot of incoming study abroad and exchange students, which meant I began to have a real desire to do the same thing myself, and initially I was looking at a couple of other universities like Georgetown. I think NYU was one of the options, and I actually met a guy from Cal who was like, "You should come to Berkeley and study. It's an amazing institution. You'll love California. It's so similar to Australia, and I'd I'd I'd actually been to California before my first overseas trip when I was 19, and so I had a taste of California already. So initially, I was looking at the whole sort of Cal system, the whole you know UC system. So I looked at UCLA, UC San UCSJ maybe and anyway yeah and and then I fell and I fell in Berkeley as the final one just because what a great city to live outside of you know San Francisco's such a beautiful city and and yeah so I ended up spending an entire year there which was just like you know life defining. Michael Hingson  09:57 What'd your mom think of that? Paul Bugeja  10:00 Yeah, typical of mum's. There was a lot of tears at the airport, but you know, and this was you know like at a time when social media was really not even happening, so it was all about the phone calls regularly. But she was happy. She's I'm very lucky in that, even though I'm an only child, mum's not a clingy a clingy mum, you know, she has always encouraged me to just go out and do everything that I possibly can, and and she would never, she would rarely, you know, get get in the way of me living out my life and my dreams. Michael Hingson  10:33 Do you still? Is she still here? Paul Bugeja  10:35 She is. Yep, she's um 78, so she's you know I'm still a youngish older person, and even though we don't, we sort of you know like see each other as much as maybe I'd like because we don't live in the same place. You know, we we talk every two days or so on the phone, and I stay in regular contact. And yeah, it's it's still a very very strong relationship. Michael Hingson  10:56 That's cool. That that's a good thing though. So you you went to Berkeley. You were here. You were out here in California for a year, and then what happened? Paul Bugeja  11:05 Well, I actually I bounced back to Australia, feeling very encouraged to to follow my acting pursuits because I I did a couple of shows at when I was at Cal. I did one drama class as well in the drama department, you know, made some lifetime friendships and and felt very connected to myself as an actor again. And so, even though originally my plans were to apply to become a diplomat through the Department of Foreign Affairs and Trade, the acting thing was a bit too strong. So I came back and and felt a little not torn, but certainly I had to I had to weigh up the competing desire to want to be an actor against the fact that I had a great degree that I could maybe go on and do something completely different with. So in fact, I spent a year thinking about that and ended up quite on a different track and enrolled in a master's of environmental studies, which you know was something that interested me definitely. And but decided that I would, in addition to drama school as well, which I did do, and I got into. So I did one year of that master's, and then I went on to study at the Victorian College of the Arts, which is one of the big three drama schools in Australia, and so I finally got to that took that circuitous route to drama school, despite my mum's earlier advice, and she was happy because you know I got there under my own auspices in terms of I'd made a decision as an adult to finally get there, rather than maybe as an excited teenager who you know could obviously do so many things, and so I had both the academic degree, and now I was into a program that I'd always wanted to sort of be involved with. Michael Hingson  12:49 Right. Well, and and that that's fine. That makes sense. Yes. So I'm not sure when to bring this up. So I'll bring it up now. Sure. Tell us about your dark angel. Paul Bugeja  13:01 Yeah, absolutely. So probably in my in my in my late 20s, I started working at a university in back at University of Melbourne. Actually, my old alma mater, and by then, you know, I was actually you know sort of I I was doing some acting, you know, some professional acting, not a lot of it, but enough to sort of be remain interested. So I needed a part time job on the side, you know, to to keep it going as most actors do. And when I started working at the university, I became very interested in fitness as well. I joined a gym and started going to the gym there and made some sort of friends with the local personal trainers. And one day I was doing some training and on one of the big, big sort of bouncy medicine balls that you can sit on for balance and training work, and one of the instructors came up to me and said, "Do you realize that your scapular wings? And I was firstly thinking, "Well, what the hell is my scapular? And then I sort of made sense that it was my shoulders, you know. And and I said, "What do you mean? He said, "Well, when you do upper body workouts, your scapula has quite a lot of movement in it, and it's quite visible. Now, I've always been a very thin person, like I've always sort of been. We've joked about being a tall, skinny dude, you know, and and so I I'd never thought anything about maybe the fact that my my shoulder blades were a bit more prominent. I figured that was because I was a slim person, you know. Of course, so he recommended I see a physiotherapist, and I did. I saw a sports physio in case I'd injured myself or there was some underlying issue. After a couple of sessions with a sports physio. I was referred to a neurologist because the sports physio had some inklings about it may be being a neurological condition potentially of some kind, but had no idea what it might be. And this is when I guess my dark angel first really. Began alerting me to its presence in the background of my life, and I'll explain why I call it my dark angel in a moment. Yeah, the neurologist and I did some tests, and I went in for a biopsy, a muscle biopsy, and I was diagnosed with one of the variants of muscular dystrophy, which is fascioscapiohumeral muscular dystrophy, so it affects the face, the humerus, and the scapula, but in general affects the muscles across the body. It's a degenerative neuromuscular disease. It's not that common; about one in 8000 have it. So you know, enough people have it that it's out there. Some people live with live with it their entire lives and don't know they have it for the reasons that I've just sort of elaborated on, which are it can it can be there but be so minor that you just think it's because you're a slim person or you don't have much you don't go to the gym so you don't work out so your muscles aren't growing or whatever. So yeah, and I was not that thrown by it at the time. It was it was in our family, so it wasn't that much of a surprise to me that maybe I had it. Given that another family member, even though they're quite distant on the family tree for me, also had it, and yeah, I began to just think about you know like what life would be like with this condition, and you know began to have regular sort of checks with the neurologist and you know other sort of allied health professionals around how to manage that. Luckily, it was very my and still is very mild in terms of how severe that it can be. But as I sort of began thinking more about my professional life. I I actually took on a an editing and writing degree and a screenwriting degree as I started to move away from acting because I figured I am a creative person. I love writing and I want to improve my craft. I was interested in journalism as well and I could do that as part of this degree. Paul Bugeja  16:58 So I started studying and that then led to me actually writing a couple of books, four or five books, working as an editor, and then at one point I began thinking, I think I need to write my own book about my journey with this condition, or you know, disability, whatever you want to call it. And I had watched the TV show Dexter, which you may or may not have watched. Yep, and Dexter talks about his dark passenger. You know, as and that's the the sort of I mean, it's a weird correlation. I know in some ways, but that's the serial killer in him. That's his dark passenger. But it really resonated as um this idea of there being this sort of passenger in your life. You know, for whatever reason, whatever it is, and I didn't obviously want to steal that sort of figurative term, but I began thinking about a dark angel instead because, for me, it's a double thing. I mean, I was whatever Catholic. I'm not a practicing Catholic anymore, but you know, the notions of angels around us is something you know we all sort of think about, I guess. But the notion of my scapular wing and those being wings as well was very sort of resonated with me, and so I began feeling that for me my entire life this dark angel had been somewhere in the background, very very far in the background to the point where I wasn't even really aware of that dark angel, and then of course when the diagnosis came along, the dark angel began to make its presence more known, and yeah, and and then over time, I'm very, I live with, you know, like anyone with any sort of disability or chronic medical condition, like you live with it 24/7, and some days it's more of a burden, other days you don't not even aware of it, but you have to learn to live with it, and and so I now feel like I have this sort of dance with the dark angel, I like to call it, who sometimes is more present in my life and sometimes much more in the background. Michael Hingson  18:53 So, what kinds of things does it sort of limit you, or what what do you have to do to to make sure you don't let it get too much of a control over you. Paul Bugeja  19:04 Sure. So for me, the biggest thing I ever did was start going to the gym. You know, I did that just out of pure practicality because there was a gym on campus. It was very easy to join it. It was very close to go to on my lunch break, and so I've now maintained a really rigorous gym schedule, even though my upper body strength is quite weak and limited. I've been able to, I think, the my GP and say allied healthcare professionals like physios and exercise physiologists and occupational therapists have all commented that my gym program is one of the things that may you know this it's a may but may have prevented the condition progressing more severely than it has. So staying fit has been really important. I think by nature, I like to call myself a pragmatic optimist or optimistic pragmatist. By nature, I'm a practical person. I sort of feel as though, unlike I mean, look, everyone manages the news of some sort of health situation differently. You know, some people it can lay low, and I understand why because it can be very confronting, and every condition has a different set of limitations, like you know, it can be quite severe for some people. Like my my cousin had a different form of muscular dystrophy, Duchenne muscular dystrophy, which meant that he was in a wheelchair from the age of five and died at the age of 28. So you know, like like in my case, I feel blessed on some level that my condition is slowly deteriorating, but I do think that I'm lucky that I have enough of a practical and positive attitude about not letting it. I don't call, I never ignore it or or deny it, but I call about. I just resist it. The resistance is there. Like I I push back against it. So mentally, I try to stay positive physically. I try to stay healthy, but you know it does limit me. I have part of the condition. I have something called foot drop, which means that my feet catch a lot as I walk. So I trip a lot. So I I have damaged elbows and knees a lot because of that. So as a consequence, I have to be conscious when I walk. It's not just a. It's not like for most people, walking is an unconscious action. Of course, for me, it's a conscious action to ensure that I trip less. And of course, as I get older, tripping becomes a thing as you get older anyway, because you know your muscle tone changes and you know all kinds of things. So you know, it's about almost in a way you have to become. You do have to be aware of it all the time, and you have to manage it all the time. But that doesn't mean it has to become a burden. I think in many ways it's pushed me the other way, which is it's made me have a lust for life. It's made me want to do more. It's it's probably pushed me to be more nomadic while I can be, just in case there's a point where I can't be, and that sounds a little bit sad, and I mean probably in some ways, but I see that as a positive. Like a really small example I can give you is whenever I visit my mum, like I don't drive, so I use public transport like trains and busses and and the like. And if I catch a train to to go visit my mum, she always insists I'll come and pick you up at the at the train station, rather than you walk to my place, and I insist every time I'm going to walk because while I can walk, I want to walk. You know, so I don't. It's not. I reject. I don't reject her kindness, and I understand it. But it's me saying to the dark angel, "No, I will. Does she? Michael Hingson  22:36 Does she understand Paul Bugeja  22:38 it? I think so on some level, but she still Michael Hingson  22:41 wants to come and get you. Of course, Paul Bugeja  22:43 she does. Of course, there can be the tiniest trickle of rain, and she's like, "Oh, you can't walk in that rain. You know, I've got an umbrella, mum. No, no, no. You know, it's all that stuff. Um, it's it's delightful of her, and I'm glad, and I'll always expect the offer in those situations. But um, yeah, no, she um, you know, unfortunately, and I think a lot of parents will who pass on genetic conditions because this is a genetically passed on condition for me. She feels a sense of guilt about you know having passed on through her line, and so I think she we've talked about it a few times, and it's not a heavy weight on her shoulders, but she has a sense of it. Yeah. Michael Hingson  23:20 Well, I I appreciate that. What was it like when you first got the diagnosis? Though, did it did did it depress you? Did it kind of knock you on your ear in in any way, or did you really decide almost right from the beginning? Okay, this is here, but I can deal with Paul Bugeja  23:37 it. Yeah, it look, you know. So I'm writing a book about this, as I was saying at the moment, and in the in the chapter of the book that I'm writing, I think I wrote something along the lines of life just moved on. You know, like there was no discernible difference. Like I didn't feel physically any difference because there was no physical difference. But for me, I mean, you know, I I work in the media and I've worked in the knowledge industries of any kind for quite some time. Knowledge is power, you know. And and I would rather know about something and then be able to to to have some agency about how to act on it than to bury my head in the sand. Or, but by the same token, I can understand that knowledge can really throw some people. And you know, I have a friend, for example, who I was diagnosed with MS, and that can be an awful condition to be diagnosed with because it can progress very quickly. And for her, the knowledge wasn't great. You know, it's it's been a very big challenge for her. But you know, five years on, now that she has much more knowledge about it because she's had to live with it, she's going the opposite way. So you know, everyone is different, but for me, the knowledge actually catapulted me forward rather than weighed me down. Michael Hingson  24:46 Well, that was a choice that you had to make, or that you got to make, and you made it. And you're you're choosing to move forward with life, which is great. Paul Bugeja  24:55 Yeah, yeah. I feel lucky. As I said, I know. Everyone can can make that choice because of their own set of circumstances, and I do feel lucky about some of my circumstances. And you know, so I don't think everyone can necessarily be that practical or optimistic about things. But I encourage people to you know take a breath and and try and sit with whatever it is that they have to manage at any particular time, because you know people. A lot of people have a lot heavier challenges than I do, and they meet them as well. So it's possible to meet your challenges, I think, even if it limits you still. Michael Hingson  25:36 Well, so it's something that you live with, and so on. And I appreciate that. What what makes you get out of bed every day and and move forward, or is that what what you've been describing? Paul Bugeja  25:48 Look, I think I mean you know I'm I'm an I'm a lark, so I'm at about 430 in the morning, and I'm a Monday person, and I had this conversation with someone just this past Monday at the gym who you know dragged herself into the gym, and she was you know can't be bothered. I hate Mondays so much, you know, blah blah blah. And I get all that, you know. People love their weekends and a break. I love, I love the beginning of a day, and I and I have no problems getting up because I love the thought of there being so much in front of me, you know. And and even as as I grow older, and and you know, life obviously begins to go into a different phase. I still feel there's so much ahead, and and and it sounds a little bit Pollyanna of me, maybe, and a little bit overly optimistic, and a little bit Hollywood. But you know, I feel so hungry for life, and and even though that doesn't mean my life is perfect by any means, and that every day is perfect, and that there are some days that are are challenging. I face that all the time, as do we all in our different ways. But I I just feel so eager for the things that I mean. I have a great professional life, I have a great personal life, I have great friends, I have a good family. You know, my health is fine given the situation. Doesn't mean it's perfect, like I just said. But I don't have much to complain about, really. So, really, getting up is each day is is not a hard thing for me. It's it's it's a joy most days. Michael Hingson  27:15 So, are you married? Paul Bugeja  27:17 No, single. And this is, and I often frame conversations with this because sometimes my friends say to me, "Gosh, you have a great life, and I say, "Yeah, but I chose to be single, to not have children, and to not have pets-the three big things that change the course of your life sometimes in a good way, quite often. But also, I have more choices ahead of me because I am single and childless and petless, you know. Michael Hingson  27:42 Yep. Paul Bugeja  27:43 But you know, I don't. I'm not. I don't. I don't feel. I feel like I could have made other choices around this, of course. And I don't think there is a right or a wrong choice. It's just you have to find the right choice for you, especially when it comes to these big life choices. Michael Hingson  27:59 Well, you know, and when I got married, my wife and I had discussions about children, and she felt that she didn't want to have a child because she was in a wheelchair, and she felt in her specific situation, it would have been a lot harder on the body, and she would have been in bed a whole lot during a pregnancy, and she was afraid she would lose a lot of the the upper body strength and so on that she had. And my belief was that was her choice to make, and so we we both decided that we didn't want children. We would very happily entertain our nieces and nephews and throw them out of the house at the end of the day and send them home, which worked out really well. Paul Bugeja  28:49 I can I can understand that choice, and I I certainly I always thought I would be a father to be to be honest about that. When I was in my late teens and early 20s, it was forefront of my mind. Even though I had all these other adventures planned, and I had a couple of opportunities, actually, probably in my 30s, where I could have chosen to go down that road. And yeah, around the time I was diagnosed, I began thinking what that might mean. Like, and I began to not fear passing on my my FSHD to my potential children, but because often it passes through the female to the male, so it's less likely to pass through me. But if I had a female child, I might have passed it on genetically to her, who then passed it on to my grandchild. And not that that should stop anyone ever wanting children, but to your point and and the way you and your wife discuss the situation, I I made a conscious decision that probably given the life choices I was making around my career as well and other and personal life, it might not be the best choice. So yeah, I can understand where where. If Speaker 1  30:04 you enjoy Unstoppable Mindset and would like to help us continue bringing these conversations to you each week, we've created a way for you to support the show. Your contribution helps us cover production costs and continue sharing stories, insights, and ideas that inspire people to live with purpose and possibility. If supporting the podcast feels right for you, you'll find the link in the show notes. Thank you for being part of the Unstoppable Mindset Community. Michael Hingson  30:36 So, in in your life, what is one of the well? What would be the greatest thing in your life, personal or professional, that you've experienced so far? Paul Bugeja  30:47 The greatest thing, yeah, it's a it's a great question. That's a Michael Hingson  30:52 toughie because there are probably several. Paul Bugeja  30:54 Yeah, no, there are, there are. I mean, you know, I think, and this will seem a little sort of not so great. I mean, as in not great. Sorry, but I think the the first job in journalism that I got, which was working for the Guardian, the Australian Mars said version of the Guardian, that was pretty amazing for me because I had I had thought, and it wasn't as a journalist. It was as a like a community sort of an audience sort of person, basically. So I wasn't writing and I wasn't generating content, but just to be finally in a media organization after probably 10 or 15 years of always thinking, God, I'd love to work in the media. I'm a real news hound. I love news. I love current affairs, and even though for some it was just getting a job, for me it was taking a step into something that I had thought about for a while, and finally, and you know, working for a really reputable and very well known masthead as well, that had a lot of credibility. So that was pretty exciting, and and that sort of set me on the path of, I think this is where I will stay now if I can. Even though, as you would know, the media is under a lot of pressure to sort of evolve with a lot of external threats to the way it works and and you know staying financially viable. So I've sort of put myself into a very hot pot, and I hope I'm not the frog that jumps out. But I don't think I will be. I think I've managed to forge a bit of a career now that will keep me going. So yeah, it's not a a life like sort of fireworks sort of moment, but it was a it was certainly the day that I got the phone call saying we'd we'd love you to come and join us was was you know very similar to that? I got the phone call from drama school saying you got into drama school. It was a real like everything felt lifted. You know the whole I felt like I was floating that day. Michael Hingson  32:52 Yeah, I'm with you. So what other kinds of jobs then did you progress to over time? Paul Bugeja  32:59 Yeah, so because because I was pursuing acting for for quite some time, probably for about 10 to 15 years, really. You know, I had to do what most actors do, which is work a lot of other jobs. You know, like you just have to. The work is never constant, even for the for the biggest actors in the world. You know, I mean, most of them obviously work constantly, but you know, like to be a working actor is is never let anyone say that being an actor is not a real job. It's a really hard job, you know. And so, I I worked for a long time in casual jobs. I worked in a lot of theaters in in like the sort of the ticketing sort of area of of theaters. So I worked at both the Sydney Opera House and the Victorian Art Center, two big theater. You would know the Sydney Opera House, obviously, but yeah, Victoria Arts Center is another big theater organization in Australia. And while I was doing that, I began doing some freelance editing as a book editor. This was where I really began getting interested in content and copy, and and I had the part-time job at the university while I was studying and sort of doing all these other casual things and acting, and a role came up working in digital sort of content with a large betting agency. So you know, sports betting, which is very big in Australia, and it was managing their blog, their sports blog. So lots of content about what's happening in all the different sports, but you know, sort of a marketing slash copy role. But it was my first foray into digital content, you know, and this was at a time when it was really starting to amp up, and that therefore, you know, made me really think much more about journalism and and wanting to pursue that. So that was sort of the springboard into working in digital marketing, working as a sub editor, and then sort of finally landing this role at the Guardian, which didn't last super long, unfortunately, because I was completing a master's in publishing and communications at the time, and discovered that I. I'd left I'd left Melbourne to move to Sydney to work in the role and had two subjects left and I'd been told by the university that I could complete them in Sydney, and then I was told by an administrator that that was not possible, so I had to leave my job at the Guardian to go back to Melbourne to finish the masters, which was fine to do, and I kept doing other casual kind of jobs and you know contract roles. Well, I did that, but it meant leaving the Guardian, which was a bit disappointing. But it meant I got my masters, which was really critical because again, that was more of a springboard onwards. In fact, I, as part of my masters, I went to China and did a an intensive class in Shanghai, and from that, got offered a role in China, in Shanghai, with a with a Chinese media company that that produced content for for the very big expat community in Shanghai, and I was about to leave to go to Shanghai to take up the role, and you'll you'll probably will have a wry smile, which was February 2020, and fortunately, not long after that, everything kind of went pear-shaped with COVID, and so had to. I mean, it's sort of lucky in a way because Shanghai had a pretty awful time during COVID, where it was a very strict lockdown. So I probably dodged a bit of a COVID bullet in that regard, even though Australia had its own share of lockdowns. But yeah, so that sort of threw a bit of a spanner in the works of what looked like the next part of my media career. But then, of course, you know, I'm a I'm a fatalist. I I run with fate. I I don't push back against the things that sort of maybe look like negatives or or take us off our path. Paul Bugeja  36:38 And I just feel like it's another another fork in the path that takes us on a on a route that will hopefully get us to where we were meant to be, and not taking that role meant, of course, about a year later, I saw the job with Stuff, which is the New Zealand media company that I currently work for, and that was the middle of 2021. It was based in Auckland. We were still in the middle of COVID, but I applied anyway because why not? And yeah, they offered me the role pending the borders opening, effectively. And luckily for me, there was a two-week window where New Zealand and Australia thought things were going to go okay, and the borders opened, and I jumped on the first flight out and got myself to Auckland, and then I started my current job, or actually a different version of my current job with stuff. Michael Hingson  37:27 And what is your your current job? Paul Bugeja  37:30 So I am currently I create digital content for stuff for stuff digital, as we're called now. I mostly create trivia quizzes, so fun daily quizzes that we have a very very dedicated audience for. People love a quiz. I also create a word puzzle called the Hard Word, which is an anagram kind of puzzle. I create that every day. I create a news quiz for them. I also help manage the community, the online community that interacts with with us as another part of my role, which is the role that I originally went to New Zealand for, but as a full time gig, and now it's just sort of part of my my role. So yeah, I am a quizmaster. I love it. I had previously worked in television quiz shows during my time in Australia when I was juggling other stuff, so I had a bit of a background in in quiz question writing and quiz research and verifying, and so I'm now really in such a wonderful job. But I always like to be very clear about this to people because it sounds like the best job in the world. Wow, sitting and making cool quizzes every day-it's a really involved job, and it it takes a lot of kind of like time to research and put together these quizzes because you know you're trying to please a very broad audience of from you know 15 year olds to 75 year olds. So you know, it's it's a it's a very involved job, even if it's a fun job, and so it does, you know, it it does still have a very critical kind of like professional aspect to it, even though it sounds like to some of my friends and and people who learn about it the best job in the world. Michael Hingson  39:17 Well, I'm sure it's a great job, but it is a clearly a challenging job. Have you ever encountered people who talk to you about making your your quizzes or trying to work with staff to make quizzes and some of the things they do more accessible? So, like people who are blind can solve the quizzes or work the quizzes and use screen readers and so on to do the same things that others do. Paul Bugeja  39:45 Excellent point. So yeah, I feel quite often when I'm making my quizzes that clearly they are for an audience that can access them very easily. You know, as opposed to an audience that might need assistance to access. Them and you know we do the the the basic stuff as we you know you must you know um like you know putting an alt tag so that um you know people who maybe are but are able to to use to access the quiz as a as a an audio rather than a video rather than a written um quiz but you know, I think you're right. And look, to be fair, I think you know the way that the media is going. The media is going very video oriented now, anyway. I think, which is a brilliant thing for people who do need have some access, because you know, with the video, of course, a video quiz, there'll be audio as well as visual, as well as the written word potentially. So there's a way that covers off all the bases, you know, or you know, many of the bases anyway. At the moment, you know, we are starting to bring in some minor changes, but I think going forward, it's pretty critical because you know the world is very aware that people do have some limitations in the way that they can access, especially digital content, and even though there are a lot of great forms of software that you can use to to make like your your life less limited by whatever you know sort of limitation you may have, it still isn't as good as it can be. And and I think certainly as someone with a disability, I'm an advocate for disability. You know, I'm on the board of a major disability organization in Australia. I'm on an engagement advisory committee for the same organization. I'm very pro and very much an advocate for ensuring that anyone with any form of disability can access and have as as great a life as possible, as untrammeled. I'm not untrammeled. That's the wrong word. As as as you know, as a life that has no barricades to them, basically. Michael Hingson  41:49 Well, the the reality is that crossword puzzles, for example, can be made accessible. Yep. And of course, I wouldn't expect the organization to suddenly produce Braille puzzles, but there are there are still ways Speaker 2  42:11 to do it Michael Hingson  42:11 to create audio, for example, kinds of things. And you mentioned the the value of video that only works if people truly put the appropriate descriptions in in audio form, the video, which a lot of people don't do, which is unfortunate, but it is possible to make to make them more accessible than they are. Paul Bugeja  42:36 Yeah, but it is a but it is a it is Michael Hingson  42:38 a challenge, and I hope that over time more more kinds of things will be accessible. I get the New York Times online, and a lot of what they do isn't nearly as accessible as it should be, and I can see how it it could be made more Accessible, but they haven't just been really willing to do it. And and ironically, a lot of the media has been one of the places where access has has truly not been addressed nearly like it it should be. And and the the result of that is that there are problems, and of course they say, well, things change so fast. They they do, except that it's all about coding and it's all about understanding programming and coding. And if you do it right, and if you know it, you can keep up either way. But you know, people don't necessarily do that. Paul Bugeja  43:38 Yeah, look, I agree, and I think you know. Look, without I'm not going to become a defender of the media, even though I'm part of it. But I think they definitely can do better as a as an entire sort of profession. I think that the tricky thing for the media at the moment is, I mean, you look at what happened this week. You know, 300 reporters, you know, sacked at the Washington Post. You know the media is under a lot of pressure to be financial, and that's not a great defense against not being accessible, mind you. But their mind is on survival at the moment, and that's an unfortunate thing because it means that they can't do the stuff that would actually benefit everyone, you know, their entire audience. So, not to defend it, but that's that's the only sort of rationale I can think of as to why they're not doing more. But that shouldn't stop them trying. That shouldn't stop them trying. Michael Hingson  44:32 Well, and I think that's really the issue: is that people do need to try, and people need to make an effort. And if they would, it would help a lot more than than it does today. Paul Bugeja  44:43 Agreed. Michael Hingson  44:44 So, if you could change one thing about your life, what would it be? Paul Bugeja  44:47 Not very much. Like I really love my life. You know, I I I even and this will sound quite odd. I even probably wouldn't change having a disability. You know, like it it who I am. It's it's in my. You know, it's it's so it's in my DNA. Like you can't get any deeper into someone than their DNA. You know, like of course I'd rather not have this, but it's it it it doesn't as we've discussed. It doesn't stop me. It doesn't limit me. It just modifies my life on the edges. It's Michael Hingson  45:16 just it's just part of you. Paul Bugeja  45:18 That's exactly right. And so I have to embrace that. You know, as you know, does anyone with any sort of situation that is slightly left of you know what people might call you know normal or ordinary, you know? And I, I always say I try to live my life less ordinary, you know, and and I think it's that attitude which really stands me in good stead because when you choose like I like as we discussed earlier, I'm in a position where I can make different choices to people who do have a partner, or do have kids, or do have a massive mortgage, or do have whatever you know job that keeps them in one place. But you know, you know the old saying about you make your own luck, right? And circumstance does change things definitely, and some circumstances are outside of our control. For example, getting having a genetic disability is outside of my control, but you know you do make your own luck as well. And I sort of feel that I am so about agency, and I'm so about you know like taking responsibility for your actions that I feel that everything about my life is because of the choices that I've made, and I want to own that. So you know why would I want to change any of that? In terms of, if I want to change it, then I will change it. So I think I have a great life. I'm healthy. I'm happy. I've got a you know like I was saying earlier, I have great friends, a good family, a great job. I'm able to you know like talk to people like this about things and and and like it's yeah life's pretty life's pretty good for me. Um, you know, there are things about the world I'd like to change, like as would we all, you know, like, um, but those things we can only sort of change on the edges, and I do that as much as I can as well. So, well, there are things that we don't Michael Hingson  46:54 have control over, and and if we worry about them, that's just going to cause us grief. It's not going to bother others. Paul Bugeja  47:01 No, no worries. Worry. I mean, I worry about something. Of course, I do. We all do. But you know, eventually, I manage to bat most of my worries away because I realize, as you said, it's usually something that is out of my control. It's funny when I talk to my actor friends, and speaking for myself, of course, you know, actors have to rehearse. You know, we rehearse favorite. You know, you rehearse for roles and whatever, and that sometimes for me has meant that I tend to rehearse things prior to you know the situation. So it means that my mind goes at 100 miles an hour about a lot of things, and that can lead to anxiety and worry. You know because you overthink, you worry about a situation that hasn't even occurred yet. You're thinking, not over. Well, that's exactly right. That's exactly right. So, you know, I think the the biggest lesson I've probably taken as well from my diagnosis and and the the thing I committed to this year a little bit as a part of my New Year's resolution or whatever you want to call it is to just be as present as I can. You know, like to live in this moment right now. That doesn't mean I don't have an eye to the future, and and I don't make plans, and I don't am not excited about the future. But I'm I'm trying to be as present as I can because if you're present, then all then all this worry disappears in a way because you just can only deal with with with what's right in front of you. Michael Hingson  48:18 Right. Do you have any regrets? Paul Bugeja  48:22 Um, not really. I mean, you know, like there've been a few moments in my life. So, for example, I can I can name a few things. Like when I was in my early 30s, I entered the the diversity visa program, which is the green card lottery in America. Yeah, and I I got it. I got a green card, you know, and so I was all ready to move to the states back in the late 90. Oh no, when was it? Yeah, the late 90s. Yeah, yeah, um, early noughties, and I got into the writing editing course in Australia. So I was really enjoying that. I was doing some acting and some paid acting work, and so I had to. I had a moment where I was like, "Well, do I really want to take up this green card off and become a resident of America? I have lived there before when I studied. I travel there regularly to see my friends, you know. And so I had this crunch time. It was a sliding doors moment. I I did visit a few times. I spent a bit of time in the states, and then I eventually dropped the green card. Now, occasionally, I look back on that and think, "Was that a silly thing to do with what would have opened up to me had I moved to the states? You know, like would my acting career have taken off? Would I have ended up working for the New York Times? Look, whatever it is. So there's a sense of regret about it, but it's such a faint shade of regret that it doesn't it doesn't hold me back. You know, I don't want to be held back by anything in my life. And I think, for me, regrets can hold you back too much. You know, oh yeah, Michael Hingson  49:49 yeah. Oh, absolutely. Well, and and it seems to me that that it's one of those things that could have gone either way, as you said, a sliding door moment. I think that's a really interesting way to put it. But but the fact of the matter is, you made a choice. You're happy with the choice, and you may or may not have been as happy with the choice if you had moved to America. But you wouldn't have experienced a lot of the things that you have experienced. So it's okay. Paul Bugeja  50:14 That's exactly right. That's exactly right. So even you know occasional relationships that went awry, or you know what else? Gosh, what if I stay pursue my career as an actor? There are always going to be what ifs with life, you know, and it's the what ifs that tend to cause us regret. I think, and Michael Hingson  50:29 well, and and cause us so much fear. Paul Bugeja  50:32 That's exactly right. And regret and fear should be the same word, effectively, because that's all that's playing. And if you can find a way to manage that as best you can, and and look. I always say I try to to look down at my feet on the ground to see where I am, and to look forward to see where I'm going, rather than look back where I've come from. And look, we can learn a lot from where we've come from. And in fact, the book that I'm writing is almost like a detective novel, where I track back through my life to see if I can see moments where I might have known that I had FSHD much earlier, so in that regard, I do look backwards. You know, I'm happy to to to have a critical eye on the past and to learn from it. You know, but I don't ever want it to drag me back to it. I'm always looking to be pulled forward. Michael Hingson  51:18 Well, that's the operative part, right? There's nothing wrong with looking back and and learning from what you've experienced, and and more people should should do more of that. It seems to me, but Paul Bugeja  51:29 oh yeah, let's. That's a much longer conversation, isn't it? It Michael Hingson  51:32 is. Who's been the most most influential person in your life, and why? Paul Bugeja  51:38 Yep. Michael Hingson  51:40 Besides Kate Blanchett, but that's another yeah, Paul Bugeja  51:42 of course, very influential, Kate. If you're listening, if she is, I hope she'll Michael Hingson  51:47 reach out. I'd love to have her on the podcast. But anyway, you Paul Bugeja  51:50 never know, my friend. You never know. Look, I mean, it's it's a hard question because, but it's a good question. I mean, there have been so many influences in my life, you know, and and I don't want to step on toes by not naming people in a way, but you know, for one one really influential person who has given me, you know, I have a friend who's a film journalist actually, and has written, you know, a lot mostly about the production side of the industry rather than film reviews, and I feel she only came into my life about maybe 10 or 12 years ago. So she's a relatively new friend, but a very dear friend. And I think I did an internship at a magazine that she worked for, and she was the the editor of at the time, and I think she had a really great influence on my life because she made me realize that I definitely wanted to pursue a career in the media. That I was done with journalism. That working in the media was exciting and interesting. You know, she made sure she pushed me in a lot of ways that I might not have been pushed otherwise, and she's remained a really dear and constant president in my life ever since. So yeah, I really feel like her coming into my life at that particular moment really was like critical in a lot of ways. But you know, she was one of many that have that have definitely given me great advice, or have been very supportive, or have just been there for me. So, yeah, big call out to her. She's she was being wonderful. Michael Hingson  53:29 Do you think that if you had never been diagnosed with or ever had FSHD, that your your job and your careers would have gone differently, or do you think that this was just a natural progression and FSHD is there, but it didn't really dictate what you did. Paul Bugeja  53:46 I think because of my approach to this situation, which is it's there, but it's not going to stop me. I think that look clearly, it's a physical condition, so it does limit me a little bit physically. So, like, I was never going to be like for for instance even with acting you know it did limit me a little bit with acting like there were certain things that like I can't do a headstand you know and I know that's a really a small thing but like in in drama classes there was I remember one class particularly always asked to do a headstand and I couldn't do it and this was pre diagnosis and I had I just thought it was because I was clumsy or uncoordinated or not muscular enough, so like certainly the diagnosis probably gets in the way of some some some kinds of careers that I might have pursued. But generally, you know, I'm a I'm a computer based person. I'm a knowledge and and and and content based person, and I was already going that way pre-diagnosis, so you know I don't think it really intervened in where I would have gone, whether it helped me or not, or whether you know it was part of the reason why I'm where I am. Look, I think it's it's part of the reason of everything that I do. You know, even if it's not all. That the defining reason, but it's it's a consideration definitely. Michael Hingson  55:04 Well, it is, and and it's helped build your resilience, and there's nothing wrong with that. Paul Bugeja  55:10 Yep, and that's right. And I'm in a career that requires resilience, and so it definitely, in that regard, yes, it's it's helped me build that further resilience. Michael Hingson  55:18 So there you go. Has AI helped you in terms of any of the things that you do on your job? Do you use it to to help in finding out information about quizzes or or that you put in quizzes or any of that? Has AI been a useful tool for you? Paul Bugeja  55:35 So again, this we could talk about this for 12 hours a time. Topics right, especially working in the media. I am. I love the fact that I'm an early adopter. Right, I love technology. I I embrace it. I'm you know I'm that guy who gets the new iPhone not every year but every other year. You know, I I'm really I embrace the new. You know, I was doing digital content well the beginning like not at the beginning of it all but you know I was I was I jump in quickly with AI I have reservations I certainly you know I tend to still use standard search but of course now with Google search AI is built into that Google search so I am using it in that regard as a media organization, we have a very strict policy about AI, as one must. You know, we have to be very careful because while it's definitely the next big revolution for everyone, whoever you are, from you know like a dog walker to a you know president, like it's going to affect everyone's lives, you know. I feel as though, so you know, for example, as a media organization, we're encouraged. We are looking at improving the way we work with AI, but there always needs to be a human oversight. Yeah, Michael Hingson  56:57 absolutely. Paul Bugeja  56:58 Yep, yep. And you would appreciate that, of course. So I don't use it in the way I think. I I think over time I will have to use it because I won't have any choice. But you know, we in the media, I think we're looking at. I don't think this is giving anything away, but we're looking at agentic AI more than generative AI because agentic AI is really useful. If I can ask an AI bot to put together the the not the quiz itself, but the the actual article the quiz will appear in that goes on the site. Well, that's just a practical like role you've given a system if you had one anyway, right? So I definitely think the media and me in in my role will will more and more embrace agentic AI as we're able to build it into our systems to help us with mundane practical tasks that you'd give the intern, that you'd give the the first year journal student out or whatever. Right? In terms of generative AI, I I've used it a bit just to see what it will throw back at me, and for example, I do a lot of quizzes as a quizmaster because I love to just do quizzes. I can tell a quiz that's been made with AI. It's very clear. I did a quiz the other day, and I kid you not. The first question was, "If I'm a Bolivian, what country might I come from? Now, I mean, for an editor or the actual person who put together that quiz, not to realize that a that's a pretty awful quiz question, but but it's such an obviously AI generated quiz question, you know. So yeah, I think we I think, and I'm also very aware that the amount of money that's being poured into AI at the moment is looking like a big bubble that will burst at some point, you know, because they can't keep plowing all this money in and expect big returns because it's not returning anything at the moment to them. Really, that doesn't mean it's not going to continue. That doesn't mean that we shouldn't embrace it. That doesn't mean that it's not going to maybe find a cure for cancer. Like I feel like there is a lot of positive that can come from it, so long as the humans stay in control. Michael Hingson  59:03 Well, I think that's the the real issue in the operative part of it. I have used AI in in writing articles, and the way I've used AI is I've I've asked it to give me give me your thoughts on or write an article about, and I'll do that like about six or seven times, and I will go through all of the things that that are created, and it gives me ideas. But I would never let it write the article, and I I would never do that because I want it to be me. And even if it could get to the point where it truly emulates me, it's not me, and I wouldn't want to do that. I so I'm I'm with what you're saying. Paul Bugeja  59:44 Yeah, yeah, and I think that's the trick. My, I think probably like with all you know, sort of new ages of technology, whether it was just the internet, and then it was sort of probably social media was the next big you know sort of critical juncture, and now it's AI. You know, it it means that the a younger. Generation that comes along that only knows this. So my my probably biggest concern would be, and I don't have children, but you know for my friends' children and the children that are going to grow up with AI, that they come to rely on it so heavily that they lose the ability to critically think, that they that they believe everything that AI says, and it will get better and it will get more accurate, but it's still throwing back. So I'll give you one quick example. When I was playing around with it back in 2022, I think, or whatever year the Queen died, Queen Elizabeth II died. I asked it, "Who's the current monarch of England? And I kept bringing Queen Elizabeth II back, and I kept arguing with it, and it kept saying no, and I started feeding it New York Times articles, Guardian articles, you know the Telegraph articles, and I kept saying these aren't reliable sources. Now this was you know back three or four years ago now, but that really concerned me, and I fear that that's the only fear for me is that people will lose their curiosity and their own ability to critically think and and and rely on it so heavily that they forget how to do really simple tasks that we should still be able to do. Michael Hingson  1:01:04 If you could change one thing about the world, whether it's big or small or whatever, what would Paul Bugeja  1:01:10 it be? I actually, so this will reveal me as a like a bit of a almost a communist. But I wish that people's obsession with money would change. I would love to change that. Like I love that people want to be comfortable and they want good lives and that we want our creature comforts and that we want to travel and have a great TV and all that somewhere to live. But I do feel li

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore groundbreaking advancements, regulatory updates, and strategic partnerships shaping the future of patient care and drug development. Revolution Medicines has achieved a significant milestone with the FDA approval of its RAS inhibitor, daraxonrasib, for metastatic pancreatic cancer treatment. This approval follows an impressive presentation at the American Society of Clinical Oncology meeting that garnered widespread acclaim. Targeting one of the most challenging cancers, this advancement offers renewed hope for patients with limited treatment options and sets a potential new standard in pancreatic cancer therapy. In another promising development, Amgen and AstraZeneca have successfully completed a Phase 3 trial for their drug Tezspire in eosinophilic esophagitis. This success positions Tezspire as a formidable contender in the competitive landscape of inflammatory disease treatments, directly challenging Sanofi and Regeneron's Dupixent. The focus on biologics targeting specific inflammatory pathways underscores ongoing innovation in this area, offering enhanced treatment options for patients. On the regulatory front, the FDA has expanded its authorization for Tivicay, an HIV medication, to include newborns. This move aligns with global efforts to advance pediatric HIV treatment and address public health challenges. Additionally, Roche has secured further FDA approval for diagnostic tests linked to Jazz Pharmaceuticals' oncology drug Ziihera, emphasizing the critical role of companion diagnostics in personalized medicine. Meanwhile, strategic initiatives are also taking shape in pricing agreements. The Trump administration is preparing to announce "most favored nation" pricing agreements with mid-sized biopharma companies as part of ongoing efforts to tackle drug pricing issues. Although these arrangements could lead to lower drug prices, they may also face industry resistance due to potential impacts on revenue. Flagship Pioneering's Profound Therapeutics has partnered with the Gates Foundation in a $35 million effort to discover new drug targets for preeclampsia—a dangerous pregnancy complication. Such collaborations are vital in accelerating research and offering innovative solutions to complex health problems. Artis Biosolutions is expanding its synthetic DNA and mRNA production capabilities with a new facility in Spain. This development highlights the growing importance of genetic medicines and reflects an industry shift towards next-generation therapies like gene editing and RNA-based treatments. On a global scale, CEPI is supporting Minapharm's Ebola vaccine candidate advancement into clinical trials amid a growing outbreak. This initiative is part of a broader strategy to enhance epidemic preparedness through rapid vaccine development and deployment. Another significant move comes from McKesson's $2.25 billion acquisition of Precision Medicine Group. This acquisition aims to strengthen McKesson's oncology and biopharma segments, emphasizing precision medicine's growing role in personalized cancer treatment. In the context of geopolitical dynamics, concerns about Chinese dominance in clinical trials and supply chains have been raised by Congressman Nathaniel Moran. This highlights strategic dependencies and underscores the need for robust domestic capabilities in biopharmaceutical research and manufacturing. In clinical developments, Bausch + Lomb faced setbacks with its phase 2 trial combining dry-eye disease drugs Xiidra and Miebo but remains optimistic as it advances to phase 3 trials. Conversely, Spyre Therapeutics is deprioritizing its anti-TL1A antibody approach following underwhelming phase 2 results for rheumatoid arthritis—a testament to the rigorous validation process required before new therapies can reach patients. Akeso's success with its PD-1xVEGF bispecific antibody ivonescimab in biliary tract cancer demonstrates innovative biologics' potential to expand treatment options beyond traditional indications. In regulatory news concerning Capricor Therapeutics' Duchenne muscular dystrophy therapy, an extended FDA review period reflects careful regulatory evaluation following additional data submissions. These developments paint a picture of a dynamic landscape where scientific innovation is paralleled by regulatory challenges and strategic partnerships aimed at addressing both market demands and pressing health issues. The continued focus on personalized medicine, competitive dynamics in biologics, and global collaboration efforts underscores a transformative period for pharmaceuticals and biotech industries. As these sectors evolve, they hold the promise of delivering more effective treatments worldwide while addressing unmet medical needs across various domains.Support the show

FDA extends its review of Capricor Therapeutics' Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the rapidly evolving landscape of pharmaceutical and biotechnology sectors, several significant developments have marked recent progress in drug development, clinical trials, regulatory approvals, and industry partnerships. A landmark partnership between Roche and Hanmi Pharm has been established to develop HM17321, a promising weight loss drug. This collaboration involves a substantial $190 million upfront payment and could reach up to $2.3 billion based on milestone achievements. The high stakes underscore the potential value of addressing obesity through innovative pharmacological interventions, highlighting industry focus on metabolic disorders. Roche's recent $2.5 billion agreement with Hanmi Pharmaceutical emphasizes addressing metabolic disorders through less-explored mechanisms, indicating confidence in its potential to target obesity through novel pathways. Further illustrating industry dynamism, Lundbeck has reported impressive financial performance with a 16% sales growth in the first half of 2026. This growth is driven by the success of Vyepti and Rexulti. Vyepti, an antibody-based therapy for migraine prevention, continues to capture market share due to its efficacy and safety profile. Meanwhile, Rexulti extends Lundbeck's influence in treating major depressive disorder and schizophrenia, solidifying its position in neurological therapies. Significant advancements on the regulatory front have been made for drugs targeting rare diseases and neurological disorders. Spruce Biosciences is advancing toward a fourth-quarter FDA filing for its Sanfilippo syndrome drug following successful manufacturing discussions. This enzyme replacement therapy targets an ultra-rare lysosomal storage disorder with profound neurological impacts on affected children—a vital step forward in addressing unmet medical needs in rare diseases. Moreover, multiple drug approvals across various regions underline regulatory successes. The European Commission has approved Acadia Pharmaceuticals' Daybue (trofinetide) for treating neurobehavioral symptoms in Rett syndrome patients. This approval follows successful Phase 3 trial results and marks an important milestone in managing this severe neurodevelopmental disorder. Similarly, Takeda's Orzeyful (oveporexton), a first-in-class orexin receptor agonist for narcolepsy type 1, has been approved in Japan, emphasizing advancements in targeting orexin deficiency—a key driver of narcolepsy. In oncology developments, Bayer's Hyrnuo (sevabertinib) received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for HER2-mutant non-small cell lung cancer based on promising Phase 1/2 data. This tyrosine kinase inhibitor represents a novel approach to targeting genetic mutations within cancer cells. Additionally, GC Biopharma's Hunterase has gained approval in India and Taiwan for treating Hunter syndrome (mucopolysaccharidosis type II), utilizing enzyme replacement therapy to address this lysosomal storage disorder affecting multiple organs including the central nervous system. Notably, this therapy demonstrates an ability to cross the blood-brain barrier—a significant technical achievement enhancing treatment efficacy. The regulatory landscape is also evolving with new guidelines such as the UK's MHRA clarifying pathways for microbiome-based medicinal products. These developments underscore the growing interest in microbiome therapies as promising approaches to treating infectious diseases. Amidst these advancements, challenges persist as seen with Regenxbio facing a 22% share drop following an FDA clinical hold on its Hunter syndrome gene therapy RGX-121 due to spine MRI findings. This situation highlights inherent risks associated with cutting-edge gene therapies despite their groundbreaking potential. Overall, these scientific developments and regulatory updates illustrate a vibrant pharmaceutical and biotech industry focused on innovative treatments addressing complex diseases. This momentum promises enhanced patient care while signifying a robust pipeline of therapeutic options poised to transform disease management paradigms across multiple domains. The industry continues to witness significant scientific advancements and regulatory shifts. GlaxoSmithKline's (GSK) achievement of securing the world's first regulatory approval for a hepatitis B vaccine in Japan underscores GSK's leadership in infectious disease prevention—a critical advancement in global public health efforts. Moreover, collaboration between Roche and Eli Lilly culminated in FDA approval for an innovative Alzheimer's biomarker blood test. This diagnostic tool offers a groundbreaking development in Alzheimer's disease management by providing a less invasive method for early detection and monitoring—crucial for improving patient outcomes and tailoring therapeutic interventions. On strategic corporate fronts, Daiichi Sankyo is enhancing its oncology portfolio by promoting Ken Keller to head a new commercialization unit aimed at becoming a top-five oncology player by 2035. This reflects broader industry trends toward specialized therapies offering substantial clinical benefits. Cell therapy sector dynamics are also evident as Cellares' CEO plans operational resizing after losing a significant manufacturing client—a reflection of broader industry dynamics where scaling innovative therapies like automated cell therapy requires balancing operational capabilities with market demands. Berry Street's merger with Healthify aims to expand AI-driven metabolic care by integrating Healthify's AI technology with Berry Street's clinical network—aligning trends toward personalized medicine and digital health integration. On the regulatory front, Spruce Biosciences progresses towards filing for FDA approval of its ultra-rare disease drug candidate emphasizes commitment to developing treatments despite complex pathways promising significant impact for underserved populations. Lastly, TME Pharma remains optimistic about its brain cancer drug nearing partnership conclusions reflecting confidence despite competitive pressures—highlighting key scientific advancements shaping pharmaceutical landscapes emphasizing innovative therapies' focus on improving patient care outcomes through enhanced diagnostics novel therapeutics comprehensive healthcare solutions. Recent developments highlight significant scientific advancements poised to influence patient care trajectories as Capricor Therapeutics received a three-month extension from FDA reviewing additional data refined indication Duchenne muscular dystrophy therapy candidate deramiocel set November 22 action date underscoring FDA commitment thorough evaluation processes providing potential new treatment option pending approval. In contrast, Regenxbio faces FDA hold RGX-121 gene therapy candidate aimed at Hunter syndrome due to small nodules cystic masses spines patients registrational trial highlighting ongoing challenges gene therapy rigorous safety assessments complexities developing advanced genetic treatments. With Roche entering substantial agreement Hanmi Pharmaceutical access investigational obesity drug HM17321 next-generation asset aims induce weight loss enhance lean mass positioning potentially transformative therapy burgeoning weight management market reflecting growing interest competition obesity treatments strategic focus expanding metabolic disorder portfolio. Regulatory business maneuvers paralleled broader industry trends including shifts manufacturing strategies essential advanced therapies innovative approaches underscored recent discussions vivo delivery systems reshaping viral vector production improving efficiency scalability potentially lowering costs accelerating time-to-market further highlighting rigorous safety standards governing clinical research drug development processes landscape therapeutic development continues evolve companies like Novo Nordisk trialing lower maintenance doses oral Wegovy obesity treatment gained significant market traction initiatives reflect ongoing efforts optimize dosing regimens enhance patient compliance outcomes collectively underscore dynamic period pharmaceutical biotech sectors characterized scientific innovation strategic investments regulatory scrutiny implications profound patient care new therapies promise address unmet medical needs navigating complex environments adapt changes influence future drug development strategies therapeutic landscapes significantly events signal not only challenges opportunities companies strive bring novel treatments market safely effectively ultimately aiming improve patient outcomes various disease areas poised intersection technological innovation oversight driving advancements hold potential enhance care expand possibilities.Support the show

In this episode Kiran Chawla sits down with Barry Posey, the father of 19 year old Blake Posey as they discuss his son Blake's diagnose of Duchenne muscular dystrophy and heart failure and how the community stepped up to help make memories for the family.Timestamps04:14 Living With Heart Failure06:02 Saying Everything Now11:17 Forrest Frank Concert Wish15:14 Community Rallies Around Blake19:58 Cars, Wheels, and Bucket Lists26:11 Making Memories Together29:10 Thankful for Every DayLocal Sponsors for this episode include:Neighbors Federal Credit Union:Another Chance Bail Bonds:Family Worship Center ChurchTwin Team Realty If you are looking to buy or sell your home, look no further!Call (225) 354-9761 Today!Sound and Editing for this audio podcast by Envision Podcast Production:

A baker's dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the financings, which included money for a potential challenger to Amgen's blockbuster Tepezza and a new venture from immunology professor Georg Schett with backing from Deerfield Management, Boulevard Bio.The analysts also discuss new approaches to drug cancer's “undruggable” β-catenin pathway, and whether Capricor's latest regulatory move will give Duchenne muscular dystrophy therapy deramiocel new life at FDA.View full story: https://www.biocentury.com/article/660539#BiotechFinancing #DrugDevelopment #BetaCatenin #DuchenneMuscularDystrophy #Biopharma00:00 - Introduction02:18 - Venture Rounds12:02 - Drugging β-catenin18:12 - Capricor & FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics' Duchenne muscular dystrophy therapy and Replimune's advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

Dyne Therapeutics is an early-stage company gearing up for its first launch, promising to tackle unmet need in patients with neuromuscular disease. President and CEO John Cox outlines the science behind the company's ambitions, and the expansion efforts that will support its metamorphosis from early-stage company to fully-fledged biotech.Key Points• Dyne Therapeutics is pioneering a new delivery method for its products targeting neuromuscular disease.• With two launches planned, the business is preparing to transform from early-stage company to fully-integrated biotech.• Shared clinical and commercial pathways for Dyne's primary disease areas allow for capital investment efficiencies.Introductions [00:06]Host Joe Coletti introduces John Cox, President and CEO of Dyne Therapeutics, a clinical-stage biotechnology company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.Dyne's journey to commercialization [00:47]Dyne spent 2025 validating its delivery platform. In 2026 it aims to transform itself from an early-stage to a commercial company, with its first product launch scheduled for 2027. Novel drug delivery method [02:09]While most genetic therapies approved for use in the past 10 years have been delivered to the liver, Dyne's technology is designed to deliver direct to the muscle and the central nervous system.Evidence of effectiveness [03:37]The technology allows for higher-than-typical dosage, but with a favorable safety profile. Trials are showing an improvement in function from baseline for patients with Duchenne muscular dystrophy and myotonic dystrophy.Capabilities and capital investment [06:22]The company is drafting in new capabilities to prepare for product launches. With $900m on the balance sheet, it is well capitalized. Its disease areas share the same clinical and commercial pathways, allowing for efficient capital allocation.

Atteint de la myopathie de Duchenne, Amor mène depuis des années un combat hors du commun. Face aux limites de la médecine classique, sa mère Michaella a choisi d'explorer une voie révolutionnaire pour lui offrir une chance. Elle nous raconte son histoire bouleversante, son combat quotidien et la nouvelle campagne lancée pour permettre à Amor de continuer à avancer... et surtout de retrouver une vie sociale. Un témoignage d'une force rare.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a wave of exciting advancements and strategic movements shaping the landscape of this ever-evolving industry. Starting with a significant breakthrough in cell therapy, the FDA has granted approval to Orca Bio's Tregzi, a novel treatment aimed at preventing graft-versus-host disease (GVHD) in blood cancer patients undergoing allogeneic transplants. This approval emphasizes the potential of regulatory T cells in mitigating the severe complications that often accompany such transplants. The success of Tregzi not only marks a pivotal moment for cell therapy but also heralds a new era in transplant medicine where cellular therapies can significantly improve patient outcomes by reducing GVHD incidence. In other strategic moves, Ipsen's acquisition of Memo Therapeutics for up to $796 million highlights the industry's focus on addressing unmet needs in transplant medicine. Memo's work on monoclonal antibodies targeting the BK virus—a significant threat to kidney transplant patients—reflects a growing trend towards personalized medicine and targeted biologics. This acquisition is poised to bring much-needed therapeutic interventions to market, underscoring the sector's commitment to innovative solutions. Meanwhile, Anthropic is making waves with the introduction of Claude Science AI Workbench, accompanied by an internal drug discovery program aimed at neglected diseases. This initiative underscores the transformative role of artificial intelligence in drug discovery, particularly in areas previously overlooked due to limited commercial incentives. By accelerating the identification and development of novel therapeutics, AI-driven platforms promise breakthroughs in treating rare and neglected diseases. In clinical trial news, Abivax has reported promising Phase 3 safety data for obefazimod, a miR-124 enhancer targeting ulcerative colitis. By alleviating previous cancer-related concerns, obefazimod stands out as a potential small molecule oral therapy for autoimmune conditions. This advancement demonstrates ongoing innovation in small molecule therapeutics designed to modulate immune responses, expanding treatment options for ulcerative colitis patients. On the financial front, several companies are bolstering their pipelines through significant funding efforts. Alvotech has secured a $75 million term loan to enhance its biosimilar pipeline, reflecting the increasing importance of cost-effective biologic alternatives. AB Science has raised approximately $2.62 million focusing on oncology and rare diseases like acute myeloid leukemia (AML) and amyotrophic lateral sclerosis (ALS). Additionally, Flare Therapeutics' $85 million Series C round emphasizes precision medicine approaches targeting transcription factors, illustrating the industry's dedication to precision medicine. Regulatory landscapes are also shifting with Sarepta Therapeutics' FDA acceptance for full approval bids on Amondys 45 and Vyondys 53 despite confirmatory trial challenges. These therapies leverage exon skipping technology for Duchenne muscular dystrophy treatment, highlighting the intricate balance between accelerated approvals and robust clinical evidence requirements. In mergers and acquisitions news, Kimball Electronics' acquisition of Helvoet Polymer Technologies expands their drug delivery systems capabilities across Europe and India. This strategic alignment reflects broader industry trends towards integrated service offerings and global expansion efforts. Regulatory challenges continue with leadership changes at the FDA as Vijay Kumar steps down amid ongoing turbulence within gene and cell therapy sectors. Additionally, Angitia Biopharmaceuticals' termination of its Phase 3 trial for its BMP-6 candidate illustrates inherent risks and strategic pivots often necessary in drug development. Turning our focus globally, China's approval of its first CAR-T therapy for solid tumors signals a pivotal moment in oncology. This milestone could spur similar advancements worldwide, particularly drawing interest on when such treatments might receive approval in other regions like the United States. Moderna's expansion into in vivo CAR-T therapies for autoimmune diseases further marks a strategic divergence from traditional approaches, aiming to create off-the-shelf solutions that redefine treatment paradigms. Gene therapy continues to gain traction as Uniqure navigates regulatory reversals from the FDA regarding its Huntington's disease gene therapy filing for accelerated approval. This development hints at a broader shift within regulatory bodies towards fostering innovation in rare disease treatments under new leadership directives. Industry-wide trends also reveal a notable shift towards automation in cell therapy production led by companies like Cellares and Ori. This reflects growing demands for scalable manufacturing processes that enhance production capabilities while reducing costs. Overall, these developments illustrate a dynamic landscape where scientific innovations, strategic partnerships, regulatory adjustments, and technological integrations drive progress across various medical fields. As these sectors evolve, they hold vast potential for transforming patient care through groundbreaking therapeutic options and improved healthcare delivery systems worldwide.Support the show

El Papa León XIV visita Canarias, donde se reúne con migrantes en Arguineguín y Tenerife, y lanza un contundente mensaje a Europa y al mundo sobre la inmigración, instando a no acostumbrarse a la muerte en el Atlántico y el Mediterráneo. Se destacan las emotivas historias de Pa, un migrante gambiano, y de Ignacio, un niño con distrofia muscular de Duchenne cuya operación milagrosa se produce tras las oraciones del Papa. En el ámbito político-judicial, se revelan las joyas de Zapatero, valoradas en 1.3 millones de euros, y las reuniones de "Lady 10" con Ábalos para proteger a Sánchez, así como sus encuentros con la Fiscalía General, que generan indignación y peticiones de dimisión. El Congreso, por su parte, da el primer paso para blindar la ley de eutanasia, con la oposición de PP, VOX y UPN, quienes defienden la prudencia y los cuidados paliativos, en un debate que coincide con el discurso del Papa en defensa de la vida. A nivel internacional, Donald Trump anuncia un principio de ...

Darrel Jr., who lives with Duchenne muscular dystrophy and was the recipient of a heart transplant. Their story spans nearly three decades of parenting, caregiving, navigating challenges, celebrating milestones, and learning how to find joy in almost every situation. With warmth, humor, and honesty, Darrel and Chaikia share what they've learned about partnership, resilience, faith, and raising a son who continues to inspire them every day. From funny family stories to lessons learned along the way, this conversation is like sitting around the kitchen table with friends. Whether you're a parent, caregiver, or simply someone who appreciates stories about love, family, and perseverance, you'll walk away from this episode encouraged. We hope you enjoy this conversation with two genuine and joyful people.

We love to hear from our listeners. Send us a message.This is Episode 1 of a four-episode in vivo-focused special series of Cell & Gene: The Podcast. Host Erin Harris speaks with Cassie Gorsuch, Ph.D., CSO at Precision Biosciences, about the rapid evolution of in vivo gene editing and the scientific, translational, and regulatory hurdles shaping the field. Dr. Gorsuch discusses how Precision Biosciences approaches in vivo therapeutic development through its Arcus platform, with programs targeting chronic hepatitis B and Duchenne muscular dystrophy. They cover the broader challenges facing in vivo gene editing, including delivery limitations outside the liver, balancing specificity and efficiency, mitigating off-target risks, and translating promising preclinical in vivo data into clinical success.Subscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Viral Video of Policemen assaulting a citizen, Student Fundraiser for kids with Duchenne muscular dystrophy, Independence Day, Arrest of Deputy Head of State Security Service, Georgia's role as a transit hub at risk.Thanks for tuning in!Let us know what you think and what we can improve on by emailing us at info@rorshok.com Like what you hear? Subscribe, share, and tell your buds.Video of Policemen assaulting a citizen: https://www.facebook.com/watch/?v=835745415874754 Trump Tower in Georgia to be built on land part-owned by the son of a US sanctioned leader: https://www.theguardian.com/world/2026/may/25/trump-tower-georgia-tbilisi-land-part-owned-son-us-sanctions-leader?CMP=share_btn_urlDemocracy Dies in H.R.:https://www.nytimes.com/2026/05/18/world/americas/actually-democracy-dies-in-hr.html?smid=nytcore-ios-shareWill Armenia–Azerbaijan peace spell the end of Georgia's transit monopoly?: https://oc-media.org/will-armenia-azerbaijan-peace-spell-the-end-of-georgias-transit-monopoly/ Check out our new t-shirts: https://rorshok.store/We want to get to know you! Please fill in this mini-survey: https://forms.gle/NV3h5jN13cRDp2r66Wanna avoid ads and help us financially? Follow the link: https://bit.ly/rorshok-donate

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency's two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary's tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge.Eli Lilly's David Ricks was the highest paid pharma CEO last year, but J&J's Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace's list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%.Finally, Amgen's rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos' initial approval. Now, it's been linked to 20 deaths in Japan.

This week I sit down with Paula Naughton from Roscommon, mum to three boys Archie, George, and Isaac. All three were diagnosed with Duchenne muscular dystrophy (DMD, a life-limiting illness with no cure.Sadly Paula lost her son Archie at just 16 years old. George and Isaac, now also 16, continue to live with the condition as their family fights tirelessly for access to emerging treatments and trials.In this deeply moving conversation, Paula speaks about grief in all its forms, the loss of Archie, the heartbreak of watching your children lose their health, and the reality of living with anticipatory grief while still trying to hold hope.Paula speaks with incredible honesty, strength, and insight about motherhood, resilience, advocacy, and the unimaginable balancing act of loving fiercely while living with uncertainty every day.To learn more about DMD and support the family's campaign, visit:

Text Us!In this episode, we talk to Dr. Tye Martin about his life with Duchenne muscular dystrophy, his academic career, and what it's like living with a disability.You can follow Tye on Instagram @dr.tyedmartin or subscribe to his podcast The TYEPOD HERE.Please subscribe, leave a review, and follow us on social media to know about upcoming episodes and to participate in this podcast.Instagram - @raisingdisabledpodcastFacebook - Raising Disabled Podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest news shaping the industry, from breakthroughs in cancer therapies to advancements in AI-driven drug discovery. Starting with regulatory updates, the potential appointment of Richard Pazdur, M.D., as the new FDA Commissioner is causing quite a stir. Following Marty Makary's resignation, Pazdur has emerged as a prominent candidate due to his extensive background in oncology drug regulation. Known for his commitment to accelerating cancer therapy approvals, his potential leadership could maintain or even amplify the focus on expediting innovative treatments for cancer patients. In a significant regulatory achievement, Beone Medicines celebrated the FDA's approval of Beqalzi, marking it as the first BCL-2 inhibitor approved for mantle cell lymphoma. This approval challenges AbbVie's Venclexta and underscores a growing trend towards targeted cancer therapies that offer new treatment avenues for patients. The oncology space continues to be fiercely competitive, with companies striving to deliver more precise and effective cancer treatments. Turning to clinical trials, AstraZeneca's Imfinzi has shown promising results in a phase 3 trial focused on bladder cancer patients who are not eligible for cisplatin-based chemotherapy. These findings position Imfinzi as a strong competitor to Merck's Keytruda and reinforce AstraZeneca's strategic focus on expanding its oncology portfolio through novel combinations and indications. In the realm of genetic therapies, Regenxbio has achieved a milestone with its gene therapy for Duchenne muscular dystrophy. This therapy met its primary endpoint in pivotal trials, highlighting the potential of gene therapies to address rare diseases with limited treatment options. Such successes are likely to encourage further investment in gene editing technologies, which hold significant promise for tackling conditions once deemed untreatable. The FDA is also exploring frameworks to repurpose existing drugs for new uses by leveraging existing safety data. This could streamline drug development processes and offer cost-effective solutions for patients with complex conditions. However, this approach will need rigorous validation of efficacy in new indications to ensure patient safety and therapeutic effectiveness. Despite setbacks in its Alzheimer's research, Biogen remains steadfast in its efforts. While their tau-targeting candidate did not meet primary endpoints in a phase 2 trial, reductions in tau pathology and cognitive benefits were observed. This perseverance showcases Biogen's commitment to finding innovative approaches to tackle Alzheimer's disease despite ongoing challenges. On the operational front, Taiwan's Bora Group is acquiring Macrogenics' CDMO operations for up to $127.5 million. This move reflects a broader trend of consolidation within the CDMO space as companies aim to enhance their production capabilities and streamline operations. Quality control remains a critical concern as evidenced by Sun Pharma's recent recall of a chemotherapy batch due to glass particle contamination. Incidents like these underline the importance of stringent quality assurance measures throughout the manufacturing process to ensure patient safety. Moreover, Viz.ai has launched an AI-powered pulmonary care platform aimed at integrating acute and chronic care workflows. This development signals an increasing adoption of artificial intelligence in healthcare, promising improvements in diagnostics and patient management efficiency. AI continues to gain traction as Isomorphic Labs recently secured $2.1 billion in Series B funding aimed at enhancing AI-driven drug design models. Similarly, Charles River has introduced an AI-powered digital pathology platform poised to Support the show

On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, and Tess Cameron kickoff with deals, highlighting the up to $15.2B Hengrui–BMS partnership and the broader trend of outsourcing early-stage drug development to China. The discussion continues with the co-hosts noting China's edge in speed, quality, and cost-efficiency, while underscoring that the strength of U.S. capital markets remains a key advantage. This week also saw a significant raise, with Isomorphic Labs announcing a $2.1B Series B. In regulatory news, the group described the departure of FDA Commissioner Dr. Marty Makary as creating fresh uncertainty around FDA leadership and direction as they speculated on his exit and who will replace him. On the data front, Regenxbio met the primary endpoint inits Phase 3 trial for Duchenne, though the hosts flagged potential investor skepticism around the side effects, limited data, and FDA uncertainty. Next, they discuss that Biogen and Ionis are advancing their Alzheimer's tau program despite mixed results. The co-hosts also mention Inhibrx's Phase 2 data in head and neck squamous cell carcinoma, as well as Moderna's Hantavirus vaccine research following the recent cruise ship outbreak. The episode concludes with a look ahead to upcoming conferences, including ASCO, ADA, and ATS. *This episode aired on May 15, 2026.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into a range of significant industry updates, spotlighting scientific advancements, regulatory challenges, and strategic movements that are shaping the future of drug development and patient care. The pharmaceutical landscape is often marked by rapid changes, as evidenced by recent reports indicating President Donald Trump's plan to dismiss FDA Commissioner Marty Makary. This potential leadership change is set against a backdrop of controversies during Makary's tenure, including the rejection of Replimune's advanced melanoma therapy, RP1. This therapy was designed as an oncolytic immunotherapy using a genetically modified herpes simplex virus to target and destroy cancer cells. The FDA's rejection of RP1 ignited debate over the agency's decision-making processes, which some critics view as inconsistent and lacking transparency. Such decisions can have profound implications—delaying patient access to critical treatments and affecting company financials and market dynamics. Furthermore, internal discord at the FDA during Makary's leadership period underscores the importance of stable leadership in maintaining efficiency and fostering scientific rigor. Turning to corporate developments, Gilead Sciences has revised its first-year sales forecast for YezTugo, its long-acting PrEP injection for HIV prevention. The company now projects revenues to reach $1 billion, reflecting strong market uptake. This adjustment highlights the growing demand for innovative PrEP solutions as part of broader HIV prevention strategies. Meanwhile, Daiichi Sankyo is grappling with a $610 million profit setback due to an overextension in their manufacturing capabilities for antibody-drug conjugates (ADCs). This situation illustrates the financial risks inherent in scaling production within rapidly evolving therapeutic areas like ADCs, where balancing supply and demand remains critical. In legal news, Capricor Therapeutics has initiated a lawsuit against NS Pharma concerning a breach-of-contract over Deramiocel, a Duchenne muscular dystrophy treatment. With an FDA decision pending, this legal battle underscores the complexities of partnerships and contract compliance in advancing neuromuscular therapies. On the regulatory front, Biogen and Eisai are experiencing delays from the FDA regarding their Alzheimer's drug Leqembi. These regulatory hurdles highlight the complex processes that can impact drug rollout timelines significantly. Odyssey Therapeutics' successful $304 million IPO aims to bolster its autoimmune and inflammatory disease pipeline. This reflects robust investor interest in biotech firms with promising therapeutic candidates addressing high-need areas. In terms of market dynamics, the competition between Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo is reshaping the oral GLP-1 receptor agonist market. A newly launched weekly tracker will monitor prescription trends to provide insights into how these weight-loss solutions are impacting obesity management. Additionally, Johnson & Johnson's efforts to enhance awareness around depression treatment through public health campaigns illustrate how companies are addressing mental health challenges. Advancements in digital health continue with Tether's rollout of medical AI for mobile devices and MedAptus' operational 'command center,' highlighting ongoing innovations poised to transform healthcare delivery by enhancing efficiency and patient engagement. Strategic acquisitions remain a key theme as Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion—a move that expands Angelini's footprint into the U.S. rare neurological drug market. Similarly, Blackstone's $250 million investment in Anagram Therapeutics for cystic fibrosis enzyme replacement therapySupport the show

Across seventeen separate kitchens and living rooms, the same patterns surface. Children who cannot describe their own symptoms have aggressive behaviors read as "just autism" instead of as pain, neuroinflammation, catatonia, or seizure activity. Inside these families, profound autism arrives with company: Whitney on tuberous sclerosis complex, Lydia on type 1 diabetes, Heather on SYNGAP1-related disorder, Jillian on PANS/PANDAS, Erica C. on Duchenne muscular dystrophy, Elena on Lennox-Gastaut syndrome and tonic-clonic seizures, Michelle on gastrointestinal disease. Whitney and Christine describe catatonia severe enough to require electroconvulsive therapy (ECT), a treatment most listeners have never been told is part of profound autism care. The same response keeps coming back from too many clinicians, a psych med and a restraint order in place of a workup. Diagnostic overshadowing has a body count, and these mothers can name it.Three other themes repeat. Trust yourself; you know your child best. Fierce love is a clinical skill. When the system has no service that fits your child, you build one. Mothers in this episode fight schools and therapy centers after their children are harmed or their rights are trampled. Other mothers describe building transportation services, programs, and supports from scratch because no one else would.NCSA exists because this population has been missing from the public conversation about autism. These mothers are the correction.Mother's Day 2026, NCSA released a short reel on the hour from 10am-6pm CT on Facebook and Instagram. We conducted interviews with mothers who had been nominated by the community. This podcast episode is a compilation of the 17 short stories shared. Articles for each mother with more detail will be coming soon on the NCSA website. NCSAutism.orgCHAPTERS:00:00:00 Stephanie00:02:50 Renee00:05:46 Whitney00:08:47 Susan00:10:41 Kim00:12:24 Erica P.00:14:36 Lydia00:16:48 Jen00:19:52 Heather00:23:44 Christine00:27:37 Amy00:29:29 Jillian00:32:43 Keynote: Kiki00:42:11 Erica C.00:45:44 Zuheil00:48:20 Elena00:52:44 Michelle

Canberra-based Nepali mother and registered nurse Nirjala Sigdel shares her personal journey after her two-year-old son, Liam, was diagnosed with Duchenne muscular dystrophy (DMD), a rare and progressive genetic disorder that causes muscle degeneration. She describes the diagnosis as a moment when her “world turned upside down.” Sigdel highlights the emotional and practical challenges of caring for a child with a life-limiting condition, while also advocating for access to emerging treatments, including gene therapy, within Australia. Disclaimer: Listener discretion is advised, as the discussion includes references to suicide that may be distressing for some audiences. - क्यान्बरा निवासी निर्जला सिग्देल आफ्नो छोरा लिएममा निकै दुर्लभ मानिने जेनेटिक अवस्था डुशेन मस्कुलर डिस्ट्रोफी (डीएनडी) रहेको थाहा पाउँदा संसारै उल्टिए जस्तो लागेको बताउँछिन्। यो एक गम्भीर र क्रमशः बढ्दै जाने जेनेटिक डिसअर्डर वा जिनमा रहेको एक असामान्य अवस्था हो र यो अवस्था आफ्नो एक्लो सन्तान हाल दुई वर्षका लिएमलाई पनि रहेको थाहा पाउँदाको अनुभव देखि उनी यस रोगको उपचार अस्ट्रेलियामा नै सम्भव होस् भनेर कसरी सक्रिय रूपमा आवाज उठाइरहेकी छिन् भन्ने बारे पेसाले रजिस्टर्ड नर्स रहेकी सिग्देलले बताएकी छिन्। सहकर्मी सुनिता पोखरेलसँग गरिएको कुराकानी प्रस्तुत गर्नु अघि श्रोताहरूलाई। नोट: यो कुराकानी कतिपय श्रोताका लागि विचलित पार्ने किसिमको पनि हुन सक्छ। कुराकानीका क्रममा आत्महत्याको बारेमा पनि उल्लेख गरिएको छ।

Over the past quarter-century, the state of healthcare has changed dramatically, with new cures and treatments becoming available for conditions that have been around for far longer. While there's no cure yet for Duchenne muscular dystrophy, a lot of progress has been made when it comes to research and support, and much of that progress is thanks to the Jett Foundation of Norwell. Eric Snyder, President and CEO, and Maura Carroll, the Director of Development, talk with Nichole about the Foundation's storied history, their efforts, and their upcoming event to celebrate their 25th year.See omnystudio.com/listener for privacy information.

A father sets out on a journey across Slovakia, walking from Košice to Bratislava - not for sport, not for adventure, but to try fundraise money to help save his two-year-old son, William. The boy suffers from Duchenne muscular dystrophy, a rare and devastating disease, and the family is racing against time to access experimental gene treatment. This radio piece follows a father's determination, love, and the extraordinary distance he is willing to walk for hope.

Around 30% of boys diagnosed with Duchenne muscular dystrophy also experience cognitive dysfunction and neurodevelopmental disorders like autism and ADHD. A UT Health San Antonio neuroscientist is doing research he hopes will uncover what is causing these deficits and how they might be treated.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Duchenne and Becker Muscular Dystrophy⁠⁠⁠⁠⁠ from the MSK section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

A conversation with Carol RoopchandsinghHe never stopped fighting. Neither will she.Matthew Roopchandsingh - known to many as Lil Roopie - lived for nearly thirty years with Duchenne Muscular Dystrophy. He built a YouTube channel, designed his own logo, and spent his life reaching out to others with disabilities, telling them never to give up hope. He passed away on November 14th, 2024.His mother, Carol Roopchandsingh, was his caregiver, his advocate, and his guardian. She worked three jobs. She slept in hospital chairs. She fought insurance companies, dismissive doctors, and a system that too often asked: why provide care to someone who will never get better?Today, on our milestone 100th episode, Carol bravely sat with Dr. Fethke to bring Matthew's story out of the shadows - and to make sure his legacy is just beginning.I am honored to introduce Carol Roopchandsingh.—We spoke about the long and painful road to Matthew's Duchenne diagnosis, the systemic failures that denied him the equipment, therapy, and support he needed, the emotional and physical toll of caregiving with no safety net, how Matthew channelled his condition into a platform of advocacy and joy, and Carol's vision for a foundation in his memory - to fight for every person who lives with disability, that the system forgets.Lil Roopie's YouTube Channel: https://www.youtube.com/@lilroopie/featuredFollow me on Instagram and Facebook @ericfethkemd and checkout my website at www.EricFethkeMD.com. My brand new book, The Privilege of Caring, is out now on Amazon! https://www.amazon.com/dp/B0CP6H6QN4

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

Alpha Clinics in California accelerate the development of regenerative medicine therapies that use cells and genes to treat serious diseases. Patient advocate Tara Radcliffe Ghiglieri shares lived experience with gene therapy, while Sheldon Morris, M.D., M.P.H., Mehrdad Abedi, M.D., Daniela A. Bota, M.D., Ph.D., Catriona Jamieson, M.D., Ph.D., Michael Lewis, M.D., Mark Walters, M.D., and Leo D. Wang, M.D., Ph.D., describe how Alpha Clinic teams design and deliver clinical trials for a wide range of conditions, including cancer, blood disorders, neurologic disease, osteoarthritis, metabolic disorders, pulmonary arterial hypertension, and Duchenne muscular dystrophy. They highlight how coordinated networks, community partnerships, and genomic tools help expand access, lower financial barriers, and bring promising cell and gene therapies to more patients while carefully tracking safety, effectiveness, and long-term outcomes. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41168]

In this vulnerable conversation, Mary shares what it truly costs to fight for a full life in a system that too often puts up barriers. She speaks candidly about the exhaustion of proving her son's needs, the quiet ways lack of accessibility shrinks a child's world, and the urgency she feels to create memories. Most of all, she reminds us that her 14-year-old son Eddie is not his diagnosis of Duchenne muscular dystrophy — he's a teenager and a human first. This conversation is raw and deeply human.

Guest: Dr. Thorsten Boroviak is an Assistant Professor at the University of Cambridge and a member of the Cambridge Stem Cell Institute. He discusses how stem cell–based embryo models are helping researchers study early human and primate development, including implantation and gastrulation. He also talks about using primate systems such as marmoset to understand human development, the role of biomechanics and extraembryonic tissues in embryogenesis, and the ethical considerations surrounding embryo models and emerging technologies like in vitro gametogenesis. Featured Products and Resources: Explore a basic overview of organoids and resources to support your organoid culture. Explore STEMCELL Technologies’ collection of technical videos and webinars on neurological disease modeling. The Stem Cell Science Round Up Mitophagy Controls Blood Stem Cells – Embryonic blood stem cells expand while staying multipotent thanks to tightly controlled ROS levels regulated by developmental mitophagy. SLC4A3 Variants Drive Arrhythmia Risk – Mutations in SLC4A3 raise intracellular pH in heart cells, which shortens electrical signals and increases the risk of dangerous arrhythmias. HSC Dynamics After Myeloablation – After chemotherapy, blood stem cells briefly boost differentiation to rebuild the blood system before returning to normal. Modeling Duchenne Cardiomyopathy – Scientists generated heart organoids from Duchenne muscular dystrophy patient stem cells that mimic cardiomyopathy. Photo Reference: Courtesy of Thorsten Boroviak. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into transformative developments reshaping this dynamic industry, encompassing scientific breakthroughs, strategic investments, and regulatory updates.The pharmaceutical and biotech industries are at a crossroads filled with potential and challenges. A significant trend is the anticipated surge in orphan drug sales, projected to exceed $400 billion by 2032. This growth reflects an intensified focus on rare diseases, capturing increasing interest from investors despite mainstream treatments like those for obesity. The resilience of the rare disease sector, as highlighted in the Evaluate report, underscores its capacity to drive substantial industry growth even amidst regulatory shifts from the FDA.Eli Lilly exemplifies this robust growth within rare diseases, with significant sales increases. However, forecasts suggest a potential slowdown by 2026. In response, Lilly is expanding its global manufacturing capabilities, including a $126 million investment in Japan. This reflects a broader trend among pharmaceutical companies to enhance international infrastructure to meet rising global demand.On the regulatory front, the FDA has introduced a new streamlined system for monitoring adverse events, consolidating seven dashboards into a single platform. This initiative aims to enhance efficiency and save an estimated $120 million over five years, signifying a commitment to refining regulatory processes and improving drug safety monitoring.Despite advancements, challenges persist regarding drug safety and quality control. Eli Lilly has raised concerns about high levels of impurities in compounded tirzepatide knockoffs combined with vitamin B12. This underscores ongoing issues in compounded medications and highlights the critical need for maintaining rigorous quality standards to ensure patient safety and therapeutic efficacy.Corporate restructuring is also reshaping the industry landscape. Evotec's announcement of layoffs affecting 800 employees alongside site closures is part of its reorganization efforts. This move reflects broader trends where companies streamline operations to remain competitive amid changing market conditions.Technological advancements are making significant inroads into drug development processes. Whole genome sequencing (WGS) is increasingly recognized as a transformative tool for complex disease drug development, facilitating targeted therapeutic strategies and paving the way for more personalized medicine approaches.Moreover, automation and artificial intelligence (AI) continue to revolutionize R&D labs. These technologies are altering lab design and fostering scientific collaboration, leading to more efficient discovery processes and innovative drug development approaches.In therapeutic development news, small molecules are experiencing renewed interest in orphan drug research. An analysis by Evaluate shows that nearly half of the top twenty most valuable orphan drugs under development are small molecules, highlighting their potential in addressing unmet needs within rare diseases.Regenxbio has reported promising data for its Duchenne muscular dystrophy gene therapy candidate, showing functional improvements as it approaches key data milestones. Such advancements emphasize the growing role of gene therapies in addressing genetic disorders.BridgeBio Pharma has made noteworthy progress with its muscle weakness drug candidate BBP-418, demonstrating statistically significant efficacy data from a Phase 3 trial. These results strengthen BridgeBio's position ahead of an anticipated FDA filing.Conversely, Kalaris Therapeutics has paused dosing in its eye drug trial due to concerns about ocular inflammation. This pause highlights the critical importance of safety monitoring within clinical trials.USupport the show

a UCL researcher picks up the 2026 Novo Nordisk Prize for work that's shifting Duchenne muscular dystrophy from “nothing we can do” to “we can actually intervene.” Then the UK Space Agency drops fresh cash on satellite comms, because in 2026 even “space” is basically an internet argument. Elsewhere, researchers flip a magnet with a laser like it's casual, a Nature paper raises a big red flag about ancient carbon leaking out through Congo Basin la kes, and there's a quick gaming palate cleanser with League's latest patch. Oh — and Apple's here to remind your laptop it's replaceable. More on all of it at standard.co.uk — and follow Tech and Science Daily from The Standard for your weekday briefing. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some pivotal advancements and strategic shifts within the industry, highlighting how these changes are shaping the future of patient care and drug development.Let's start with Bristol Myers Squibb, which has been making headlines with its latest success in the realm of antibody-drug conjugates (ADCs). The company's ADC has reached an important milestone in a Phase 3 breast cancer trial conducted in China. This study successfully met its dual primary survival endpoints, affirming the company's significant $800 million investment in this promising drug candidate. The potential of ADCs in oncology cannot be overstated; they offer a remarkable combination of targeted therapy by harnessing the specificity of antibodies alongside the cytotoxic power of traditional chemotherapy. This approach not only enhances precision in treatment but also minimizes collateral damage to healthy tissues, showcasing the transformative potential of ADCs in cancer therapy.On the regulatory front, there are ongoing discussions about the impact of political decisions on drug pricing and innovation. The Trump administration's Most Favored Nation drug pricing policy has stirred significant concern within the biotech sector. In response, ten midsize biotech firms have united to form the Midsized Biotech Alliance of America to challenge this policy. They argue that such pricing strategies could hinder innovation by enforcing restrictive pricing models, potentially stalling the development pipeline for new therapies that address unmet medical needs.In terms of strategic corporate movements, Boehringer Ingelheim has entered into a $500 million partnership with a British biotech firm aimed at developing an oral therapy for autoimmune diseases. This collaboration is part of a broader trend towards precision medicine which focuses on modulating specific immune cells to improve treatment outcomes while minimizing unwanted side effects. It's a clear indication that companies are increasingly investing in targeted therapies that promise better efficacy and patient safety. Additionally, Boehringer Ingelheim's partnership with Sitryx underscores another trend: strategic partnerships aimed at innovative research endeavors with substantial investment commitments—potentially exceeding $500 million—to explore immune response modulation.The acquisition landscape is also seeing dynamic shifts. Asahi Kasei's acquisition of Germany's AiCuris for $920 million marks a strategic move to enhance its R&D capabilities, specifically focusing on antiviral therapies for immunocompromised patients. This acquisition aligns with growing global attention towards infectious disease research, especially in a post-pandemic era where preparedness and rapid response capabilities have become paramount.Meanwhile, Sarepta Therapeutics is undergoing a significant leadership change as CEO Doug Ingram announces his retirement. Ingram's leadership was characterized by notable advancements in treatments for Duchenne muscular dystrophy (DMD), although it wasn't without its share of challenges regarding regulatory and pricing debates. As Sarepta continues to expand its gene therapy pipeline, this leadership transition comes at a crucial juncture, potentially setting new directions for the company's future.Accent Therapeutics' recent decision to halt its solid tumor trial due to adverse events exemplifies the risks inherent in drug development. The company is now redirecting its focus towards other cancer programs, illustrating how adaptability remains key in navigating clinical setbacks.Protagonist Therapeutics has made a strategic choice by accepting a $400 million payment from Takeda instead of sharing profits from its hematology asset rusfertide. This decision may provideSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.In this Mind Moments episode, Jeff Chamberlain, PhD, joins the podcast during Duchenne Muscular Dystrophy Awareness Week to provide clinical and translational perspective on the evolving landscape of DMD biology and therapy. Chamberlain, professor at the University of Washington School of Medicine and Director of the Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center in Seattle, reflects on aspects of Duchenne pathophysiology that may still be underappreciated, including evidence that disease processes begin earlier than once recognized and the growing importance of immunologic factors in shaping progression and therapeutic response. The conversation also explores how neuromuscular specialists should approach treatment timing and combination strategies as gene-targeted therapies expand, the evolving interpretation and limitations of biomarkers such as creatine kinase and dystrophin expression, and what emerging gene therapy platforms may signal for care heading into 2026 and beyond.Looking for more Neuromuscular discussion? Check out the NeurologyLive® Neuromuscular clinical focus page.Episode Breakdown: 1:15 – Underrecognized aspects of DMD pathophysiology, including early onset and immunologic drivers 4:50 – Treatment timing, sequencing, and the rationale for combination strategies 8:00 – Neurology News Minute 10:30 – Clinical trial and real-world implications of dystrophin and CK as biomarkers 16:20 – Anticipated gene therapy innovation and safety considerations heading into 2026 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Regenxbio's MPS II Gene Therapy RGX-121 Hit With CRL FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review FDA Expands Indication for Pitolisant to Treat Cataplexy in Pediatric Narcolepsy Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events shaping the landscape of drug development, regulatory scrutiny, and industry advancement. As we navigate this complex terrain, we'll explore how these changes impact both companies and patients.In recent news, Moderna has encountered a substantial hurdle as the FDA declined to review its flu vaccine candidate, mRNA-1010. This decision marks a notable shift from the expedited processes witnessed during the COVID-19 pandemic, reflecting a more cautious regulatory approach under current administrative leadership. Analysts suggest this could indicate broader regulatory changes that might affect future vaccine approvals. Moderna's situation is emblematic of the challenges companies face in maintaining momentum post-pandemic, especially as their research and development spending saw a significant decrease of 31% last year due to completed respiratory trials. This reduction highlights a strategic pivot as the company reassesses its priorities amidst an evolving market landscape.Vertex Pharmaceuticals is making headlines with its ambitious revenue goals outside its established cystic fibrosis franchise. By 2026, Vertex aims to generate $500 million from non-CF medications, with recent launches like Casgevy and Journavx already showing promise by collectively bringing in $175.6 million last year. This diversification strategy is critical for mitigating risks associated with dependence on a single therapeutic area and reflects a broader industry trend towards strategic realignment. Additionally, Vertex remains under close observation within kidney disease portfolios, particularly with Povetacicept—an IgA nephropathy treatment—and the success of Journavx impacting market positions by offering chronic kidney disease patients new therapeutic options.PTC Therapeutics has faced setbacks with its FDA application withdrawal for Translarna, intended for treating nonsense mutation Duchenne muscular dystrophy. The decision came after receiving adverse feedback from the FDA, highlighting the complexities involved in gaining approval for therapies targeting intricate genetic conditions. Such hurdles underscore the high-risk nature of biotech ventures that are heavily reliant on regulatory timelines.Novartis is pushing forward with plans to seek full FDA approval for Vanrafia, its IgA nephropathy drug, despite not meeting primary kidney function goals in Phase 3 trials. This move aligns with a growing trend where companies pursue approval based on secondary endpoints or other supportive data when primary outcomes fall short. Such strategies underscore the competitive and high-stakes environment surrounding drug approval pathways.Novo Nordisk is expanding its production capabilities in Ireland to meet increasing demand for Wegovy, their obesity drug that's seen impressive sales in the U.S. This investment underscores the global potential for obesity treatments and highlights how manufacturing expansions are pivotal to supporting international market entry.In Europe, Amgen has secured approval for Uplizna in treating myasthenia gravis, adding another option to an already crowded treatment landscape but offering patients additional therapeutic choices. Meanwhile, AbbVie has launched a legal challenge against Botox's inclusion in drug pricing negotiations under the Inflation Reduction Act (IRA), arguing it should be excluded due to its plasma-derived nature.Ultragenyx has announced a 10% workforce reduction amid halted gene therapy plans and unsuccessful late-stage trials in brittle bone disease. These adjustments often reflect broader strategic shifts within biopharma companies as they realign focus and resources. Ultragenyx's operational challenges highlight the volatile nature of biotech ventureSupport the show

Please enjoy this rare bonus Saturday episode with Stefan Gehrig, founder of KNKG - my favourite gym bag and duffel company.Stefan also holds a PhD in Muscle Biology and worked in research studying muscle wasting disorders before pivoting into entrepreneurship. While he no longer works directly in academia, I didn't want to miss the opportunity to ask valuable questions about his expertise in muscular dystrophy, sarcopenia, and other muscle-wasting conditions.We also discuss the leap from research to building one of the most respected gym bag brands in the world - and what it takes to go all-in on a side hustle.THIS EPISODE COVERS:The story behind founding KNKGPivoting from academic research to entrepreneurshipWhat went into deciding to go all-in on a side hustleWhat muscular dystrophy is and who is at riskOther muscle wasting diseases and their individual and societal impactHow lifestyle affects muscle health and disease riskSarcopenia and age-related muscle lossWhy strength training matters for long-term healthNeurological conditions like ALS and MS and their connection to muscle wastingApplying scientific thinking to businessAnd much moreWe'll both be at the Arnold Sports Festival March 6th and 7th at the KNKG booth — come say hello.If you'd like to grab your own KNKG bag, DM me and I'll send you my 15 percent discount code.Instagram: @knkgCHAPTERS00:16 Meet Stefan Gehrig: KNKG founder, PhD, CrossFit Games athlete01:09 How Andrew became a KNKG superfan (Arnold booth announcement)02:23 KNKG's origin story: from PhD research to building bags since 201104:09 From scientist to founder: CrossFit niche + The 4-Hour Workweek spark05:30 Designing without experience: materials, factories, and manufacturing06:21 What was missing in gym bags: organization, shoe compartments, function08:02 The leap: leaving academia and going all-in on KNKG10:22 Why it worked: timing, runway, and applying the scientific method to business12:27 Arnold Sports Festival + 15% discount details13:38 The 80/20 of KNKG: product development, word-of-mouth, long lead times15:44 Muscular dystrophy explained (Duchenne, risks, treatments)19:07 Staying current in research — and why science is all-consuming20:28 Sarcopenia: age-related muscle loss and why strength training matters25:23 Training for life: resistance + cardio, hybrid programming28:18 ALS & MS: neurological causes of muscle wasting31:01 See you at the Arnold: booth details32:12 Wrap-up: where to follow KNKGSUPPORT THE SHOWIf you enjoyed this bonus episode, you can support the show by:Subscribing and checking out more episodesSharing it on social media (tag me — I will respond)Sending it to someone interested in entrepreneurship or muscle healthFOLLOW ANDREW COATESInstagram: @andrewcoatesfitnesshttps://www.andrewcoatesfitness.comPARTNERS AND RESOURCESRP Strength App (use code COATESRP)https://www.rpstrength.com/coatesJust Bite Me Meals (use code ANDREWCOATESFITNESS for 10 percent off)https://justbitememeals.com/MacrosFirst – FREE Premium TrialDownload MacrosFirstDuring setup, answer: How did you hear about us?Type: ANDREWKNKG Bags (15 percent off — DM for code)Versa Gripps (discount link)https://www.versagripps.com/andrewcoatesTRAINHEROIC – FREE 90 Day Trial (2 steps)Go to: https://www.trainheroic.com/liftfreeReply to the email you receive (or email trials@trainheroic.com) and let them know Andrew sent you

On this episode Fred Goldstein invites Steve Kheloussi, PharmD, MBA, FAMCP, Principal Consultant at Kheloussi Consulting, LLC, in the first installment of our four-part series on rare diseases. We discuss a practical overview of Duchenne muscular dystrophy (DMD), the current treatment landscape, and the evidence gaps that complicate payer decision-making. We also touch on the importance of what patients and caregivers need to maintain function, reduce fatigue, and navigate the significant emotional and practical burdens of care. This podcast is supported by an independent medical education grant from ITF Therapeutics. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please visit:  ⁠The Power of Partnership: Bridging Patients and Payers in Duchenne Muscular Dystrophy Management⁠. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

neuroscientist, former CMO, and author of Make Me Great, for an engaging conversation that redefines productivity from the inside out. Thomas shares his unconventional journey from artificial intelligence and neuroscience into marketing, leadership, and ethical persuasion, revealing how his early work in neuromarketing delivered results but ultimately felt incomplete without a human-centered approach. At the heart of the conversation is one powerful insight: when someone is making a decision, their brain is silently asking, "Make me great." Thomas explains how primal, subconscious forces drive our choices long before logic kicks in, and why people rationalize decisions only after they've already been made. He breaks down concepts like silent listening, subconscious frustration, and why talking about features, products, or credentials too early actually pushes people away. You'll also hear memorable real-world examples showing how simply paying attention, asking better questions, and listening without interruption can instantly change outcomes in business and in everyday life. The discussion expands into purpose, personal "why," and how building tribes around shared values accelerates productivity while reducing wasted effort. This episode is a powerful reminder that productivity isn't just about systems and structure. It's about empathy, intention, and making others feel seen, heard, and valued. What We Discuss   [00:00]  Introduction to Dr. Thomas Trautmann   [06:32]  Discovery of neuromarketing and business growth   [10:23]  The power of positioning and system 1 thinking   [14:19]  Silent listening and active engagement   [16:13]  Habits for unforgettable work and the 11-second rule   [17:06]  Understanding the primal brain and decision-making   [21:10]  The importance of "why" in productivity   [23:16]  Personal story: the power of revisiting your why   [24:40]  Client success story using "Make Me Great"   [26:18]  The gift of listening and neurochemistry   [29:07]  Team alignment, purpose, and the tribe concept   [31:43]  Actionable productivity tool: the "you" language   [32:58]  Where to learn more about Dr. Trautmann   [33:45]  Podcast closing and call for reviews    Notable Quotes   [09:14] "I noticed that neuromarketing was lacking humanity. Even though we are targeting the brain, we are lacking humanity." – Thomas Trautmann   [09:52] "When you want a decision from someone, that person's brain is shouting at you, 'Make me great.'" – Thomas Trautmann   [14:44] "Active listening is okay, but silent listening is silence. Listen. Write down. Ask questions to clarify. But get that thing up there in your head to shut up." – Thomas Trautmann   [17:11] "We make primal decisions that we rationalize afterwards." – Thomas Trautmann   [32:22] "If you look at my LinkedIn profile, it's all about you, you, you. Try to use the 'you' language. It's a super powerful tool." – Thomas Trautmann   [27:43] " When I smile, when I do the, you know, the nice smile with the little les here, which is called the Duchenne smile, by the way, I get a shoot of endorphin in my brain." – Thomas Trautmann   [32:17] "When you start something with someone, use the new language. Try to use 'you, you, you.' It's a super powerful tool. It's the first step to get them to say, 'He cares about me"– Thomas Trautmann   Resources   Dr. Thomas Trautmann Website: make-me-great.com LinkedIn: linkedin.com/in/thomastrautmann Book – Make Me Great   Productivity Smarts Podcast Website - productivitysmartspodcast.com   Gerald J. Leonard Website - geraldjleonard.com Turnberry Premiere website - turnberrypremiere.com Scheduler - vcita.com/v/geraldjleonard Kiva is a loan, not a donation, allowing you to cycle your money and create a personal impact worldwide. https://www.kiva.org/lender/topmindshelpingtopminds  

Most men would die for their family. How many live for them? ✊ When doctors told Jim Raffone to "go home and love his son" because Duchenne had no cure, he didn't listen. He sold his construction empire -- down to the last tool -- to fund a miracle. 12 years later, he's rewriting history through JAR of Hope.Witness the power of a father on a mission. Subscribe for more inspiration and insights.

Muscular dystrophy (MD) is a group of genetic diseases that affect about 16 to 25 per 100,000 people in the US, with the most common childhood form being Duchenne muscular dystrophy (DMD) and the most common adult form being myotonic dystrophy. The prevalence of DMD is estimated at around 1 in 3,500 live male births. Prenatal carrier screening for this is part of the ACMG Tier 3 expanded carrier panel. This is different from spinal muscular atrophy (SMA). As we recently had a patient who was a MD carrier, with affected male children, who we cared for, we decided to do a quick review of muscular dystrophy: its prevalence, genetics, and evaluation of asymptomatic maternal carriers.1. https://www.mda.org/disease/duchenne-muscular-dystrophy/causes-inheritance2.https://www.nichd.nih.gov/health/topics/musculardys/conditioninfo/causes3. https://www.nhs.uk/conditions/muscular-dystrophy/4. ACMG: https://thednaexchange.com/2022/03/30/acmg-carrier-screening-guideline-the-hypothetical-tier-3-panel/#:~:text=The%20goal%20of%20this%20ACMG,1%20in%2040%2C000%20or%20higher.

Meet Gabe, a 17-year-old ambassador living with Duchenne muscular dystrophy, laying out what hope looks like when it's tied to real science and real community. We sit down for a rapid-fire, honest conversation about the HOPE-3 clinical trial, the daily realities of muscle loss and heart health, and the surprising places strength shows up—like a firefighter's boot filled with donations that fund research and send kids to camp.Gabe doesn't just want to share a story; he wants to build a platform. His dream is to start a podcast focused on firefighters, service, and the people who show up when it matters. Along the way, we trade our own experiences with losing the ability to walk and the mental toughness it demands, keeping the conversation grounded in dignity, humor, and momentum.The episode brings together advocacy, clinical research, and the power of community action, with shoutouts to Fill the Boot and the many firefighters who make a tangible difference. Expect practical insights on navigating trials like HOPE-3, a candid look at perseverance, and a reminder that joy—yes, even in sneaker talk—belongs in every fight. If stories like Gabe's move you, help us amplify them: subscribe, share this with a friend who needs a boost, and leave a review to support more conversations that turn courage into action.

Which combination of impairments is MOST likely to be present in a 7-year-old patient with Duchenne muscular dystrophy? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects. #Npte #PT #ptboards #crushtheNPTE #study #studygram #spt #ptstudent #ptlife #sptprobs #physicaltherapystudent #physicaltherapy #physio #physiotherapist #ptlife #ptstudentstudy